## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2020-08-19_Virtual Town Hall 22_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/141606/download?attachment
link youtube: https://youtu.be/x957vZbGEmg
link slides: 
topic: COVID-19


## content

### qa


#### 1. Updates on FDA Testing Guidelines and Authorizations

QA Block 1-1
CLARIFIED QUESTION: What changes were made in the recent FAQ updates regarding screening and asymptomatic testing?
CLARIFIED ANSWER: The FDA updated its FAQs to clarify expectations for manufacturers and laboratories developing screening tests, emphasizing the need for EUA submissions for such claims. Healthcare providers may order tests for screening regardless of specific labeling, with considerations for test performance, turnaround time, and program integration provided in the FAQs.
VERBATIM QUESTION: What changes were made in the recent FAQ updates regarding screening and asymptomatic testing?
VERBATIM ANSWER: So first we updated a couple of our FAQs regarding screening and asymptomatic testing. The intent of these updates was to make a more clear distinction between what we expect from manufacturers and laboratories that are offering the - a test for screening versus what health care providers can order. So we indicated in our FAQs that we do expect developers of tests both commercial manufacturers and clinical laboratories to consult our templates for validation recommendations and to submit an EUA for theirs tests when they want to make claims regarding screening of asymptomatic individuals. And then we also indicated in our FAQ that healthcare providers may order tests that are not specifically labeled for screening. They may order such tests for screening even if they're not labeled that way. And we include in our FAQ some considerations for healthcare providers including considering the performance of the tests that they're ordering considering the turnaround time and considering different testing approaches depending on the performance of the tests and the overall testing program that they're incorporating a test into.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FAQ updates on screening, asymptomatic testing, EUA requirements
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: What are the validation expectations for tests intended for screening asymptomatic individuals?
CLARIFIED ANSWER: FDA expects test developers to consult validation templates and submit an EUA for asymptomatic screening claims.
VERBATIM QUESTION: What are the validation expectations for tests intended for screening asymptomatic individuals?
VERBATIM ANSWER: We do expect developers of tests both commercial manufacturers and clinical laboratories to consult our templates for validation recommendations and to submit an EUA for theirs tests when they want to make claims regarding screening of asymptomatic individuals.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Validation expectations, Asymptomatic screening, EUA submission
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What considerations should healthcare providers evaluate when ordering tests not labeled for screening purposes?
CLARIFIED ANSWER: Healthcare providers should consider the test's performance, turnaround time, and align their choice with the overall testing program.
VERBATIM QUESTION: What considerations should healthcare providers evaluate when ordering tests not labeled for screening purposes?
VERBATIM ANSWER: And we include in our FAQ some considerations for healthcare providers including considering the performance of the tests that they're ordering considering the turnaround time and considering different testing approaches depending on the performance of the tests and the overall testing program that they're incorporating a test into.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Healthcare provider considerations, Screening tests, Testing program planning
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: How does the FDA categorize self-tests as 'non-lab' or 'at-home' tests?
CLARIFIED ANSWER: The FDA categorizes self-tests as 'non-lab' or 'at-home' based on their authorization for home use, which includes self-testing at various non-home and non-lab locations without personnel involvement.
VERBATIM QUESTION: How does the FDA categorize self-tests as 'non-lab' or 'at-home' tests?
VERBATIM ANSWER: We had originally referred to this as at-home testing and we had changed our terminology to non-lab to try to be more clear that these tests may not strictly be performed in an individual's home but it looks like we may have caused more confusion. So we're working to clarify that. And we have had conversations with our CMS colleagues about this as well and we're on the same page there. The tests that we're referring to here are tests that FDA authorizes for home use. And when we refer to home use, we're really referring to self-testing. So the self-testing can take place in an individual's home or at another setting. So that's why we had referred to it as non-lab because the - an individual who is self-testing could do so at a school or at an airport or a sporting event or any other sort of non-home and non-lab setting where there is not personnel from that facility that's involved in the testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Self-testing categorization, Non-lab tests, FDA terminology
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: What are the specific CLIA requirements for non-lab or self-testing scenarios discussed by the FDA?
CLARIFIED ANSWER: FDA clarified that self-testing, previously referred to as non-lab or at-home testing, can occur at various non-lab settings such as schools or events, without facility personnel conducting or interpreting the tests. These are designed to be entirely self-administered.
VERBATIM QUESTION: What are the specific CLIA requirements for non-lab or self-testing scenarios discussed by the FDA?
VERBATIM ANSWER: We got some questions after the town hall last week about the reference to non-lab testing and how that matched up with the CMS CLIA requirements for testing to be done in labs that are certified by CLIA. And so I wanted to make sure to provide a little bit more information around that and what we mean by non-lab testing. We had originally referred to this as at-home testing and we had changed our terminology to non-lab to try to be more clear that these tests may not strictly be performed in an individual's home but it looks like we may have caused more confusion. So we're working to clarify that. And we have had conversations with our CMS colleagues about this as well and we're on the same page there. The tests that we're referring to here are tests that FDA authorizes for home use. And when we refer to home use, we're really referring to self-testing. So the self-testing can take place in an individual's home or at another setting. So that's why we had referred to it as non-lab because the - an individual who is self-testing could do so at a school or at an airport or a sporting event or any other sort of non-home and non-lab setting where there is not personnel from that facility that's involved in the testing. So what I mean by that is you know someone at a facility like a school or a or a sporting event for example could hand an individual a test but that facility personnel could not be involved in the sample collection or the performing of the test or the interpretation of the results. But if, you know, if there were - if we were to get to the point where we had a test that was simple enough for an individual to just, you know, perform themselves while standing outside of a building before they go in and that individual can provide the sample themselves, do whatever needs to be done to perform the testing and, you know, read and interpret the results themselves, that is what we would consider to be a self-test or an, you know, at home or non-lab test. And that's why we have put together that template for such tests that would not be performed within a CLIA laboratory.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA requirements, Self-testing, Non-lab testing
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: What is the role of facility personnel in settings like schools or sporting events for self-testing?
CLARIFIED ANSWER: Facility personnel at schools or sporting events may only hand out tests but cannot assist with sample collection, test performance, or result interpretation; self-testing must be performed entirely by the individual.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Someone at a facility like a school or a sporting event could hand an individual a test, but that facility personnel could not be involved in the sample collection or the performing of the test or the interpretation of the results. If there were to be a test simple enough for an individual to perform themselves while standing outside of a building before going in, where the individual can provide the sample, perform the testing, and interpret the results themselves, that is what would be considered self-testing or a non-lab test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: self-testing, facility personnel, role in non-lab settings
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: What templates are available for developing non-laboratory diagnostic tests?
CLARIFIED ANSWER: FDA has developed a template for non-laboratory diagnostic tests, referring to at-home or self-testing scenarios performed outside CLIA-certified labs, such as in schools, airports, or sporting events, by individuals without facility personnel involvement.
VERBATIM QUESTION: What templates are available for developing non-laboratory diagnostic tests?
VERBATIM ANSWER: We talked a little bit last week about the template for non-lab testing. And we got some questions after the town hall last week about the reference to non-lab testing and how that matched up with the CMS CLIA requirements for testing to be done in labs that are certified by CLIA. And so I wanted to make sure to provide a little bit more information FDA Webinar around that and what we mean by non-lab testing. We had originally referred to this as at-home testing and we had changed our terminology to non-lab to try to be more clear that these tests may not strictly be performed in an individual's home but it looks like we may have caused more confusion. So we're working to clarify that. And we have had conversations with our CMS colleagues about this as well and we're on the same page there. The tests that we're referring to here are tests that FDA authorizes for home use. And when we refer to home use, we're really referring to self-testing. So the self-testing can take place in an individual's home or at another setting. So that's why we had referred to it as non-lab because the - an individual who is self-testing could do so at a school or at an airport or a sporting event or any other sort of non-home and non-lab setting where there is not personnel from that facility that's involved in the testing. So what I mean by that is you know someone at a facility like a school or a or a sporting event for example could hand an individual a test but that facility personnel could not be involved in the sample collection or the performing of the test or the interpretation of the results. But if, you know, if there were - if we were to get to the point where we had a test that was simple enough for an individual to just, you know, perform themselves while standing outside of a building before they go in and that individual can provide the sample themselves, do whatever needs to be done to perform the testing and, you know, read and interpret the results themselves, that is what we would consider to be a self-test or an, you know, at home or non-lab test. And that's why we have put together that template for such tests that would not be performed within a CLIA laboratory.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Non-laboratory testing, Self-testing template, FDA authorization
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: Under what conditions can laboratories other than Yale perform the SalivaDirect test under its EUA?
CLARIFIED ANSWER: Under the EUA, other laboratories designated by Yale can perform the SalivaDirect test if they are CLIA certified for high complexity testing, acquire all specified components, and follow Yale's authorized instructions for use.
VERBATIM QUESTION: Under what conditions can laboratories other than Yale perform the SalivaDirect test under its EUA?
VERBATIM ANSWER: This is a test that was authorized under an EUA issued to the Yale School of Public Health Department of Epidemiology of Microbial Diseases. And it - the authorization specified a particular laboratory at Yale that is authorized to perform this test as well as authorized laboratories designated by the Yale School of Public Health the Department of Epidemiology of Microbial Diseases that are certified under CLIA and the requirements to perform high complexity tests. So this is a test that we authorized for Yale and they are able to distribute their instructions for use to other laboratories that are certified under CLIA to perform high complexity tests. And those other laboratories can perform this test under this EUA as long as they acquire all the components specified in the authorized instructions for use and perform the test according to the authorized instructions for use provided by Yale.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SalivaDirect test conditions, EUA requirements, CLIA-certified labs
REVIEW FLAG: False

QA Block 1-10
CLARIFIED QUESTION: What components and procedures must laboratories follow to perform the SalivaDirect test as authorized?
CLARIFIED ANSWER: The SalivaDirect test is authorized under an EUA for Yale-certified laboratories and other CLIA-certified high-complexity labs. These labs must acquire all components listed in the authorized instructions for use provided by Yale and follow those procedures.
VERBATIM QUESTION: What components and procedures must laboratories follow to perform the SalivaDirect test as authorized?
VERBATIM ANSWER: This is a test that was authorized under an EUA issued to the Yale School of Public Health Department of Epidemiology of Microbial Diseases. And it - the authorization specified a particular laboratory at Yale that is authorized to perform this test as well as authorized laboratories designated by the Yale School of Public Health the Department of Epidemiology of Microbial Diseases that are certified under CLIA and the requirements to perform high complexity tests. So this is a test that we authorized for Yale and they are able to distribute their instructions for use to other laboratories that are certified under CLIA to perform high complexity tests. And those other laboratories can perform this test under this EUA as long as they acquire all the components specified in the authorized instructions for use and perform the test according to the authorized instructions for use provided by Yale.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SalivaDirect test, Laboratory requirements, EUA authorization
REVIEW FLAG: False

QA Block 1-11
CLARIFIED QUESTION: What distinguishes rapid turnaround point-of-care diagnostic tests from other tests in terms of authorization priorities?
CLARIFIED ANSWER: Rapid turnaround point-of-care tests are prioritized for their ability to quickly detect individuals with high viral loads during acute symptomatic periods, aiding in timely identification and containment.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We feel like that a rapid turnaround test that has sufficient sensitivity especially in the period that corresponds to a patient who has symptoms, acute symptoms, those are when - those days during which for the most part that virus levels are very high and, you know, are more easily detected by all tests including these point of care tests. And you know it's really those individuals who have monitor high viral loads that that we want to especially identify as quickly as possible. And that's where these point of care, quick turnaround time diagnostics which could also molecular point of care tests can really, really aid us in this effort.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid turnaround tests, Point-of-care diagnostics, Authorization priorities
REVIEW FLAG: False

QA Block 1-12
CLARIFIED QUESTION: What characteristics make a test suitable for detecting individuals with high viral loads during the acute symptomatic phase?
CLARIFIED ANSWER: Tests suitable for detecting individuals with high viral loads during the acute symptomatic phase should have rapid turnaround, sufficient sensitivity, and the ability to quickly identify individuals with high viral loads, particularly through point-of-care diagnostics.
VERBATIM QUESTION: What characteristics make a test suitable for detecting individuals with high viral loads during the acute symptomatic phase?
VERBATIM ANSWER: We feel like that a rapid turnaround test that has sufficient sensitivity especially in the period that corresponds to a patient who has symptoms, acute symptoms, those are when - those days during which for the most part that virus levels are very high and, you know, are more easily detected by all tests including these FDA Webinar point of care tests. And you know it's really those individuals who have monitor high viral loads that that we want to especially identify as quickly as possible. And that's where these point of care, quick turnaround time diagnostics which could also molecular point of care tests can really, really aid us in this effort.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test sensitivity, Acute symptomatic phase, Point-of-care diagnostics
REVIEW FLAG: False

QA Block 1-13
CLARIFIED QUESTION: Are there specific FDA recommendations for expanding the development of diagnostic tests for point-of-care use?
CLARIFIED ANSWER: The FDA encourages the development of point-of-care diagnostic tests, emphasizing those with rapid turnaround and sufficient sensitivity to detect high viral loads during acute symptoms. Multiple authorizations have already been issued, and more are expected.
VERBATIM QUESTION: Are there specific FDA recommendations for expanding the development of diagnostic tests for point-of-care use?
VERBATIM ANSWER: I wanted to just take just a couple of minutes to basically encourage the further development of more point of care diagnostic tests. We this week authorized the third direct antigen test and so now there are three such tests that have been EUA authorized. And we want to encourage more and there will be more. We feel like that a rapid turnaround test that has sufficient sensitivity especially in the period that corresponds to a patient who has symptoms, acute symptoms, those are when - those days during which for the most part that virus levels are very high and, you know, are more easily detected by all tests including these FDA Webinar point of care tests. And you know it's really those individuals who have monitor high viral loads that that we want to especially identify as quickly as possible. And that's where these point of care, quick turnaround time diagnostics which could also molecular point of care tests can really, really aid us in this effort. So we look forward to more submissions and more authorizations. I just wanted to push that a little bit.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care diagnostic tests, EUA authorizations, Rapid turnaround diagnostics
REVIEW FLAG: False


#### 2. Clarifying Yale SalivaDirect Test and Validation Requirements

QA Block 2-1
CLARIFIED QUESTION: Do labs that contact Yale and get approval to run the SalivaDirect test need to submit validation data to the FDA, or can they start running the test without it?
CLARIFIED ANSWER: Labs authorized by Yale under the EUA do not need validation data submitted to the FDA and can run the test by following Yale's authorized instructions and sourcing the required components.
VERBATIM QUESTION: Do labs that contact Yale and get approval to run the SalivaDirect test need to submit validation data to the FDA, or can they start running the test without it?
VERBATIM ANSWER: A laboratory that has provided the authorized instructions for use by Yale and is designated as an authorized lab under the EUA by Yale does not need to get their own EUA. This is sort of, you know, similar to a distributed test kit accept that the components that are specified in the authorized instructions for use are generally all commercially available. So they're sort of required but not provided components of the authorized test. So Yale would provide the authorized instruction for use and the laboratory would acquire all of those components and perform the test as authorized.
SPEAKER QUESTION: Cynthia Flynn
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SalivaDirect test, FDA EUA requirements, Validation data
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: What is the third authorized antigen test listed on the FDA website, and is it already posted?
CLARIFIED ANSWER: The third authorized antigen test listed on the FDA website is LumiraDx, and it is already posted.
VERBATIM QUESTION: What is the third authorized antigen test listed on the FDA website, and is it already posted?
VERBATIM ANSWER: Yes, the LumiraDx, yes. ...right before this, yes. ...checking it now and it popped there.
SPEAKER QUESTION: Cynthia Flynn
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Authorized antigen tests, FDA website updates
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What requirements or conditions must a laboratory meet to be designated as an authorized lab under the SalivaDirect EUA?
CLARIFIED ANSWER: To be designated as an authorized lab under the SalivaDirect EUA, a laboratory must obtain authorized instructions for use from Yale and acquire the commercially available components specified. Once designated by Yale, the lab does not need its own EUA and can perform the test as authorized.
VERBATIM QUESTION: What requirements or conditions must a laboratory meet to be designated as an authorized lab under the SalivaDirect EUA?
VERBATIM ANSWER: A laboratory that has provided the authorized instructions for use by Yale and is designated as an authorized lab under the EUA by Yale does not need to get their own EUA. This is sort of, you know, similar to a distributed test kit accept that the components that are specified in the authorized instructions for use are generally all commercially available. So they're sort of required but not provided components of the authorized test. So Yale would provide the authorized instruction for use and the laboratory would acquire all of those components and perform the test as authorized.
SPEAKER QUESTION: Cynthia Flynn
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SalivaDirect EUA, Authorized lab requirements, Laboratory procedures
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: Are the components specified in the SalivaDirect test's authorized instructions all commercially available, and is the lab responsible for acquiring them?
CLARIFIED ANSWER: The components specified in the SalivaDirect test's authorized instructions are generally all commercially available, but the lab is responsible for acquiring them to perform the test as authorized.
VERBATIM QUESTION: Are the components specified in the SalivaDirect test's authorized instructions all commercially available, and is the lab responsible for acquiring them?
VERBATIM ANSWER: The components that are specified in the authorized instructions for use are generally all commercially available. So they're sort of required but not provided components of the authorized test. So Yale would provide the authorized instruction for use and the laboratory would acquire all of those components and perform the test as authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SalivaDirect test components, Lab responsibilities
REVIEW FLAG: False


#### 3. FDA Strategy on Semi-Quantitative Versus Quantitative Test Approvals

QA Block 3-1
CLARIFIED QUESTION: What is the FDA's perspective on semi-quantitative tests versus fully quantitative tests?
CLARIFIED ANSWER: The FDA supports both semi-quantitative and fully quantitative tests, views both as valuable, and has no preference for one over the other. The agency emphasizes the evolving application of serology technologies in the clinical space.
VERBATIM QUESTION: What is the FDA's perspective on semi-quantitative tests versus fully quantitative tests?
VERBATIM ANSWER: We welcome both. We think there's value for both. There might be, you know, enhanced value if there's some sort of titer, you know, so that it goes back to more directly measuring say antibody levels. But we are fully open and FDA Webinar supportive of both. And we think it's a good evolution of the technology to go there and are willing to work with any and all developers. So I don't - we don't have a preference over one over the other from the FDA perspective. You know, looking into how these various evolutions and serology tests could be used in the clinical space is evolving and important to watch and see where things are headed.
SPEAKER QUESTION: Jess Terivery
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: semi-quantitative tests, fully quantitative tests, FDA perspective
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: Would it be simpler to submit a semi-quantitative test first and then follow up with a fully quantitative test, or would both require the same rigor in the EUA application process?
CLARIFIED ANSWER: The FDA suggests a pre-EUA exchange with reviewers and indicates that fully quantitative assays require more validation. Submitting a semi-quantitative test first could expedite EUA authorization, but either approach is acceptable.
VERBATIM QUESTION: Would it be simpler to submit a semi-quantitative test first and then follow up with a fully quantitative test, or would both require the same rigor in the EUA application process?
VERBATIM ANSWER: I think, you know, having a conversation, you know, through a pre-EUA exchange with our reviewers would be good in this space. It, you know, there is going to be more validation for - required for quant assay. And so if you want to, you know, sort of have an EUA authorization as quick as possible doing the semi quant first and following-up with the full quant may make a good strategy for you. But we're open to either.
SPEAKER QUESTION: Jess Terivery
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA application process, semi-quantitative vs quantitative tests
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: What is the FDA's perspective on the use of calibration ranges versus standard curves in COVID-19 diagnostic tests?
CLARIFIED ANSWER: The FDA supports both calibration ranges and standard curves, recognizing value in each. It does not have a preference for one over the other and is open to working with developers to advance these technologies.
VERBATIM QUESTION: What is the FDA's perspective on the use of calibration ranges versus standard curves in COVID-19 diagnostic tests?
VERBATIM ANSWER: We welcome both. We think there's value for both. There might be, you know, enhanced value if there's some sort of titer, you know, so that it goes back to more directly measuring say antibody levels. But we are fully open and FDA Webinar supportive of both. And we think it's a good evolution of the technology to go there and are willing to work with any and all developers. So I don't - we don't have a preference over one over the other from the FDA perspective. You know, looking into how these various evolutions and serology tests could be used in the clinical space is evolving and important to watch and see where things are headed.
SPEAKER QUESTION: Jess Terivery
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: semi-quantitative vs quantitative tests, calibration ranges, serology tests
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: Does the FDA have specific guidance on the clinical applications of semi-quantitative and fully quantitative serology assays?
CLARIFIED ANSWER: The FDA values both semi-quantitative and quantitative assays, supporting their development without a preference. It monitors the clinical applications of these tests as they evolve.
VERBATIM QUESTION: Does the FDA have specific guidance on the clinical applications of semi-quantitative and fully quantitative serology assays?
VERBATIM ANSWER: We welcome both. We think there's value for both. There might be, you know, enhanced value if there's some sort of titer, you know, so that it goes back to more directly measuring say antibody levels. But we are fully open and FDA Webinar supportive of both. And we think it's a good evolution of the technology to go there and are willing to work with any and all developers. So I don't - we don't have a preference over one over the other from the FDA perspective. You know, looking into how these various evolutions and serology tests could be used in the clinical space is evolving and important to watch and see where things are headed.
SPEAKER QUESTION: Jess Terivery
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: semi-quantitative vs quantitative assays, FDA guidance, clinical applications
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: How can developers use pre-EUA exchanges to clarify validation requirements for different types of assays?
CLARIFIED ANSWER: The FDA suggests having a pre-EUA exchange with their reviewers to clarify validation requirements, especially since quant assays typically need more validation. Developers might consider first pursuing semi-quant authorization for a faster EUA and then following up with a full quant.
VERBATIM QUESTION: How can developers use pre-EUA exchanges to clarify validation requirements for different types of assays?
VERBATIM ANSWER: I think, you know, having a conversation, you know, through a pre-EUA exchange with our reviewers would be good in this space. It, you know, there is going to be more validation for - required for quant assay. And so if you want to, you know, sort of have an EUA authorization as quick as possible doing the semi quant first and following-up with the full quant may make a good strategy for you. But we're open to either.
SPEAKER QUESTION: Jess Terivery
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA exchanges, validation requirements, assay development strategy
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: What additional validation is required for a fully quantitative assay compared to a semi-quantitative assay?
CLARIFIED ANSWER: The FDA notes that a fully quantitative assay requires more validation compared to a semi-quantitative one. For a quicker EUA authorization, developers may consider submitting for semi-quantitative first, then follow with full quantitative assays.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: There is going to be more validation for - required for quant assay. And so if you want to, you know, sort of have an EUA authorization as quick as possible doing the semi quant first and following-up with the full quant may make a good strategy for you. But we're open to either.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validation requirements, quantitative vs semi-quantitative assays, EUA strategy
REVIEW FLAG: False


#### 4. Guidance on CLIA Waivers and Non-Laboratory Testing Templates

QA Block 4-1
CLARIFIED QUESTION: Should we submit EUA requests for non-facility use tests using the regular molecular diagnostic templates for manufacturers?
CLARIFIED ANSWER: You do not need to submit separate templates. Relevant sections from different templates can be combined into a single submission as appropriate for your situation.
VERBATIM QUESTION: Should we submit EUA requests for non-facility use tests using the regular molecular diagnostic templates for manufacturers?
VERBATIM ANSWER: You don't need to submit two templates. If there are things that you see that are relevant to your particular situation that are in each template you can combine them. You can pull the parts that makes sense for your situation into one document.
SPEAKER QUESTION: Trey Koshik
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA templates, Non-facility use tests
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Is the non-laboratory template suitable for tests performed outside home environments, such as schools or workplaces?
CLARIFIED ANSWER: The non-laboratory template is suitable for tests in settings such as workplaces or schools, as long as there's no CLIA certificate required. It applies to both prescription and over-the-counter screening or diagnostic tests, and is not limited to home use.
VERBATIM QUESTION: Is the non-laboratory template suitable for tests performed outside home environments, such as schools or workplaces?
VERBATIM ANSWER: All right. For, you know, diagnostic or screening situations outside of a CLIA waive environment I'll just add a little bit more color to what Toby already has said about the non-lab setting. It can absolutely be a test that can be performed by a consumer or if it's prescription by under prescription by the individual outside of a lab setting. There's going to be situations where that need some of these tests may be authorized for testing kids and so, you know, a guardian or a parent or another a person given permission by the guardian or parent to administer the test outside of a lab situation we'll be considering those populations and those authorizations. So that - in that case it's not the person doing it on themselves but it's the person doing it on a child who's not capable of doing it on themselves. And we've looked at the safety situation there as far as the actual sample collection and all the reagents that are with the test. But to expand that there will be situations in these non-lab settings like workplace, obviously home, school. FDA Webinar So this is really anywhere there's not a - going be a CLIA certificate available. And we do want to make these tests available in those settings as well both by prescription and by over the counter. And the non-lab template is for - what it sounds like as long as you're going for screening or diagnostic indications is a good one for you to look at. And it is just to add color to what Toby said it is can be outside of the home environment as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Non-lab testing template, School/workplace testing, CLIA waiver
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: Would schools need a non-laboratory template if students or their guardians perform the tests without assistance from personnel?
CLARIFIED ANSWER: Schools would need the non-laboratory use template if individuals or guardians perform the test without assistance from personnel.
VERBATIM QUESTION: Would schools need a non-laboratory template if students or their guardians perform the tests without assistance from personnel?
VERBATIM ANSWER: If it is a situation where the individual or perhaps or their parent or guardian is performing the testing without the assistance of a personnel from the facility that would be - that would fall under the new non-laboratory use template.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Non-laboratory template, COVID-19 diagnostic templates, School testing
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: Do pharmacies need a CLIA waiver certificate if their personnel assist in COVID-19 testing?
CLARIFIED ANSWER: Yes, pharmacies need a CLIA waiver certificate if personnel assist in COVID-19 testing. However, no certificate is required if the individual performs and interprets a self-test on their own.
VERBATIM QUESTION: Do pharmacies need a CLIA waiver certificate if their personnel assist in COVID-19 testing?
VERBATIM ANSWER: Yes. A lot of pharmacies do have certificates of waiver from CLIA and if they - if the personnel at that facility at the pharmacy are assisting in the testing then, my understanding from CMS is that they would expect the facility to have a CLIA certificate. If they are simply providing a self-test that the individual performs on themselves and interprets themselves then the facility would not need a certificate.
SPEAKER QUESTION: Trey Koshik
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA waiver, pharmacy COVID-19 testing
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: If a pharmacy provides only self-tests that individuals perform themselves, is a CLIA certificate still required?
CLARIFIED ANSWER: If a pharmacy provides only self-tests that individuals perform and interpret themselves, a CLIA certificate is not required.
VERBATIM QUESTION: If a pharmacy provides only self-tests that individuals perform themselves, is a CLIA certificate still required?
VERBATIM ANSWER: If they are simply providing a self-test that the individual performs on themselves and interprets themselves then the facility would not need a certificate.
SPEAKER QUESTION: Trey Koshik
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA certificate requirements, Pharmacy-provided self-tests
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: Are developers required to submit two different templates (point of care and non-traditional use) based on the testing locations?
CLARIFIED ANSWER: Developers do not need to submit two templates; they can combine relevant sections from different templates into a single submission for their specific situation.
VERBATIM QUESTION: Are developers required to submit two different templates (point of care and non-traditional use) based on the testing locations?
VERBATIM ANSWER: ...the template in particular you don't need to submit two templates. If there are things that you see that are relevant to your particular situation that are in each template you can combine them. You can pull the parts that makes sense for your situation into one document.
SPEAKER QUESTION: Trey Koshik
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: submission templates, point of care testing, non-traditional use testing
REVIEW FLAG: False

QA Block 4-8
CLARIFIED QUESTION: Can portions of the point of care and non-laboratory templates be combined into one submission based on specific needs?
CLARIFIED ANSWER: FDA clarified that portions of the point of care and non-laboratory templates can be combined into one submission based on specific needs, using only the relevant components.
VERBATIM QUESTION: Can portions of the point of care and non-laboratory templates be combined into one submission based on specific needs?
VERBATIM ANSWER: ...you don't need to submit two templates. If there are things that you see that are relevant to your particular situation that are in each template you can combine them. You can pull the parts that makes sense for your situation into one document
SPEAKER QUESTION: Trey Koshik
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: template combination, point of care, non-laboratory diagnostics
REVIEW FLAG: False

QA Block 4-9
CLARIFIED QUESTION: What are the specific requirements for obtaining a CLIA certificate of waiver for non-traditional testing environments like workplaces or schools?
CLARIFIED ANSWER: CLIA certificates of waiver can be obtained from CMS, and schools can acquire them for district-wide use. If personnel like school nurses conduct tests, a waiver is required. However, testing by individuals without facility assistance falls under the non-laboratory use template.
VERBATIM QUESTION: What are the specific requirements for obtaining a CLIA certificate of waiver for non-traditional testing environments like workplaces or schools?
VERBATIM ANSWER: Typically those would be certificates of waiver which are fairly straightforward to take out from CMS. If it is, you know, in a school we do have, you know, we have had discussions with the CLIA program at CMS and they do provide CLIA certificates of waiver to schools. They have programs in place to do that, you know, on a broad, you know school district level for example. And if it is a situation where, you know, as you suggested perhaps the school nurse is providing the test and performing the test, that is a situation where CMS would expect the school to have a certificate of waiver to provide that testing. But if it is a situation where the individual or perhaps or their parent or guardian is performing the testing without the assistance of a personnel from the facility that would be - that would fall under the new non-laboratory use template.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA waiver requirements, Non-traditional testing environments
REVIEW FLAG: False

QA Block 4-10
CLARIFIED QUESTION: Can a self-administered test authorized under the non-lab template also be used in CLIA-waived environments by healthcare providers without separate authorization?
CLARIFIED ANSWER: A self-administered test authorized under the non-lab template is automatically CLIA waived and can be used by healthcare workers in CLIA-waived settings.
VERBATIM QUESTION: Can a self-administered test authorized under the non-lab template also be used in CLIA-waived environments by healthcare providers without separate authorization?
VERBATIM ANSWER: And when we authorize - and Toby I hope this is correct, when we authorized a non-lab test for use. the self-administered it automatically is CLIA waived as well. So it can be run in a CLIA waived setting and performed by a health care worker.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: non-lab template tests, CLIA-waived use, healthcare provider administration
REVIEW FLAG: False

QA Block 4-11
CLARIFIED QUESTION: What additional safety considerations does the FDA evaluate for tests intended for use on children by adults in non-laboratory settings?
CLARIFIED ANSWER: The FDA considers the safety of sample collection and test reagents when authorizing tests for children, ensuring they are administered by a guardian, parent, or authorized individual in non-laboratory settings.
VERBATIM QUESTION: What additional safety considerations does the FDA evaluate for tests intended for use on children by adults in non-laboratory settings?
VERBATIM ANSWER: For, you know, diagnostic or screening situations outside of a CLIA waive environment I'll just add a little bit more color to what Toby already has said about the non-lab setting. It can absolutely be a test that can be performed by a consumer or if it's prescription by under prescription by the individual outside of a lab setting. There's going to be situations where that need some of these tests may be authorized for testing kids and so, you know, a guardian or a parent or another a person given permission by the guardian or parent to administer the test outside of a lab situation we'll be considering those populations and those authorizations. So that - in that case it's not the person doing it on themselves but it's the person doing it on a child who's not capable of doing it on themselves. And we've looked at the safety situation there as far as the actual sample collection and all the reagents that are with the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Safety evaluation for child testing, Non-laboratory testing settings, Guardian-administered COVID-19 tests
REVIEW FLAG: False

QA Block 4-12
CLARIFIED QUESTION: Are there any limitations on the types of populations (e.g., children) or settings (e.g., schools, workplaces) that can use tests authorized under the non-lab template?
CLARIFIED ANSWER: Tests authorized under the non-lab template can be used in settings outside of CLIA environments, such as workplaces, homes, and schools. They may be authorized for populations like children, with provisions for a guardian or parent to administer them. Tests can be made available either by prescription or over the counter.
VERBATIM QUESTION: Are there any limitations on the types of populations (e.g., children) or settings (e.g., schools, workplaces) that can use tests authorized under the non-lab template?
VERBATIM ANSWER: For, you know, diagnostic or screening situations outside of a CLIA waive environment I'll just add a little bit more color to what Toby already has said about the non-lab setting. It can absolutely be a test that can be performed by a consumer or if it's prescription by under prescription by the individual outside of a lab setting. There's going to be situations where that need some of these tests may be authorized for testing kids and so, you know, a guardian or a parent or another a person given permission by the guardian or parent to administer the test outside of a lab situation we'll be considering those populations and those authorizations. So that - in that case it's not the person doing it on themselves but it's the person doing it on a child who's not capable of doing it on themselves. And we've looked at the safety situation there as far as the actual sample collection and all the reagents that are with the test. But to expand that there will be situations in these non-lab settings like workplace, obviously home, school. FDA Webinar So this is really anywhere there's not a - going be a CLIA certificate available. And we do want to make these tests available in those settings as well both by prescription and by over the counter.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Non-lab test settings, Testing in children, CLIA waivers
REVIEW FLAG: False

QA Block 4-13
CLARIFIED QUESTION: What criteria make a test eligible for authorization under the non-laboratory use template versus the point-of-care template?
CLARIFIED ANSWER: The non-laboratory use template is for self-tests requiring no installation of instruments or personnel involvement, targeting non-CLIA environments like workplaces, homes, or schools. These tests are available by prescription or over the counter.
VERBATIM QUESTION: What criteria make a test eligible for authorization under the non-laboratory use template versus the point-of-care template?
VERBATIM ANSWER: The non-lab template is really for self-tests where there is no, you know, no need to install an instrument, no need for an individual or for personnel at the facility to be interacting at all with the test. For, you know, diagnostic or screening situations outside of a CLIA waive environment, it can absolutely be a test that can be performed by a consumer or if it's prescription by under prescription by the individual outside of a lab setting. And we've looked at the safety situation there as far as the actual sample collection and all the reagents that are with the test. To expand that there will be situations in these non-lab settings like workplace, obviously home, school. So this is really anywhere there's not a - going be a CLIA certificate available. And we do want to make these tests available in those settings as well both by prescription and by over the counter.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Non-laboratory use template, Point-of-care template, Test authorization criteria
REVIEW FLAG: False

QA Block 4-14
CLARIFIED QUESTION: Can tests authorized for prescription use in non-laboratory settings also be made available over the counter without a separate EUA?
CLARIFIED ANSWER: Tests authorized for prescription use in non-laboratory settings can also be made available OTC in appropriate situations, such as for home, school, or workplace use, ensuring safety and usability.
VERBATIM QUESTION: Can tests authorized for prescription use in non-laboratory settings also be made available over the counter without a separate EUA?
VERBATIM ANSWER: For, you know, diagnostic or screening situations outside of a CLIA waive environment I'll just add a little bit more color to what Toby already has said about the non-lab setting. It can absolutely be a test that can be performed by a consumer or if it's prescription by under prescription by the individual outside of a lab setting. There's going to be situations where that need some of these tests may be authorized for testing kids and so, you know, a guardian or a parent or another a person given permission by the guardian or parent to administer the test outside of a lab situation we'll be considering those populations and those authorizations. So that - in that case it's not the person doing it on themselves but it's the person doing it on a child who's not capable of doing it on themselves. And we've looked at the safety situation there as far as the actual sample collection and all the reagents that are with the test. But to expand that there will be situations in these non-lab settings like workplace, obviously home, school. FDA Webinar So this is really anywhere there's not a - going be a CLIA certificate available. And we do want to make these tests available in those settings as well both by prescription and by over the counter.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Non-laboratory COVID-19 tests, Over-the-counter availability, Prescription use
REVIEW FLAG: False


#### 5. Launching CDC Multiplex Flu and SARS-CoV-2 Assays

QA Block 5-1
CLARIFIED QUESTION: How is FDA helping CDC to launch multiplex combo flu and SARS CoV-2 assays to private labs?
CLARIFIED ANSWER: The FDA suggests reaching out to CDC as a first step, as CDC is encouraging laboratories to develop multi-analyte tests. CDC provides information and rights of reference from their EUA for laboratories to use as a basis for new tests.
VERBATIM QUESTION: How is FDA helping CDC to launch multiplex combo flu and SARS CoV-2 assays to private labs?
VERBATIM ANSWER: One thing is probably talking to the CDC would be a great thing to do. Yes absolutely second that talking to CDC would be a great first step. I can tell you that, you know, from our discussions with CDC they are absolutely in encouragement of laboratories to develop multi analyte tests like this and they are putting out information about their test to encourage laboratories to use it as the basis for new tests. And they are providing right of reference to other laboratories to use the information in their EUA similar to what they did for their single test.
SPEAKER QUESTION: BJ Tatel
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC multiplex flu/SARS-CoV-2 assay, FDA collaboration, Laboratory EUA process
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Will the launch process for multiplex combo flu and SARS CoV-2 assays differ from the FDA webinar's previous version?
CLARIFIED ANSWER: FDA notes that CDC encourages labs to develop multiplex assays using CDC's test information as a basis. The process mirrors CDC's approach with their single test EUA, providing a right of reference for validation.
VERBATIM QUESTION: Will the launch process for multiplex combo flu and SARS CoV-2 assays differ from the FDA webinar's previous version?
VERBATIM ANSWER: ...from our discussions with CDC they are absolutely in encouragement of laboratories to develop multi analyte tests like this and they are putting out information about their test to encourage laboratories to use it as the basis for new tests. And they are providing right of reference to other laboratories to use the information in their EUA similar to what they did for their single test.
SPEAKER QUESTION: BJ Tatel
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: multiplex combo assays, CDC EUA process, private lab launch
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What further recommendations do you have for laboratories using CDC's assay data for validation?
CLARIFIED ANSWER: FDA recommends submitting an EUA request, referencing the CDC EUA to avoid repeating validation, as the FDA can leverage the CDC's validation data.
VERBATIM QUESTION: What further recommendations do you have for laboratories using CDC's assay data for validation?
VERBATIM ANSWER: Yes, we would want you to come in with an EUA request for your test. But you could in your EUA request reference the CDC EUA so you would not have to repeat the validation that they have in their EUA. We could leverage that.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC assay validation, EUA request process
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: What steps can laboratories take to develop new tests based on the CDC's multi-analyte assay?
CLARIFIED ANSWER: Laboratories are encouraged to develop multi-analyte tests using information from the CDC assay. They should validate their test, obtain primers and reagents, and submit an EUA request referencing the CDC's EUA to streamline validation.
VERBATIM QUESTION: What steps can laboratories take to develop new tests based on the CDC's multi-analyte assay?
VERBATIM ANSWER: Yes absolutely second that talking to CDC would be a great first step. I can tell you that, you know, from our discussions with CDC they are absolutely in encouragement of laboratories to develop multi analyte tests like this and they are putting out information about their test to encourage laboratories to use it as the basis for new tests. And they are providing right of reference to other laboratories to use the information in their EUA similar to what they did... for their single test. So if you follow that pathway you would do your own validation of that test. And then Toby is there, you know, you would you would order your own primers and probes and reagents and validate it. Yes, we would want you to come in with an EUA request for your test. But you could in your EUA request reference the CDC EUA so you would not have to repeat the validation that they have in their EUA. We could leverage that.
SPEAKER QUESTION: BJ Tatel
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC multi-analyte assay, Laboratory test development, EUA submission requirements
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: What type of information is the CDC providing to laboratories to encourage test development?
CLARIFIED ANSWER: The CDC is encouraging laboratories to develop multi-analyte tests by sharing information about their test for use as a basis for new tests and providing a right of reference for other laboratories to utilize their EUA data.
VERBATIM QUESTION: What type of information is the CDC providing to laboratories to encourage test development?
VERBATIM ANSWER: Yes absolutely second that talking to CDC would be a great first step. I can tell you that, you know, from our discussions with CDC they are absolutely in encouragement of laboratories to develop multi analyte tests like this and they are putting out information about their test to encourage laboratories to use it as the basis for new tests. And they are providing right of reference to other laboratories to use the information in their EUA similar to what they did...
SPEAKER QUESTION: BJ Tatel
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC test development information, multi-analyte tests, EUA data sharing
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: What does 'right of reference' mean in the context of using CDC EUA information for test development?
CLARIFIED ANSWER: 'Right of reference' allows laboratories to use CDC's EUA information as a basis for developing and validating their own tests without repeating the CDC's validation.
VERBATIM QUESTION: What does 'right of reference' mean in the context of using CDC EUA information for test development?
VERBATIM ANSWER: I can tell you that, you know, from our discussions with CDC they are absolutely in encouragement of laboratories to develop multi analyte tests like this and they are putting out information about their test to encourage laboratories to use it as the basis for new tests. And they are providing right of reference to other laboratories to use the information in their EUA similar to what they did for their single test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: right of reference definition, CDC EUA usage, test development
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: Is it mandatory for developers to conduct their own validation if using CDC's EUA as a reference?
CLARIFIED ANSWER: Developers must submit their own EUA request but can reference the CDC EUA, avoiding the need to repeat validation described in the CDC EUA.
VERBATIM QUESTION: Is it mandatory for developers to conduct their own validation if using CDC's EUA as a reference?
VERBATIM ANSWER: Yes, we would want you to come in with an EUA request for your test. But you could in your EUA request reference the CDC EUA so you would not have to repeat the validation that they have in their EUA. We could leverage that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: validation requirements, CDC EUA reference, EUA submission process
REVIEW FLAG: False

QA Block 5-9
CLARIFIED QUESTION: Will the FDA accept an EUA submission that leverages validation data from the CDC's EUA?
CLARIFIED ANSWER: FDA allows an EUA submission that references CDC's EUA for validation data, so repeat validation is not required.
VERBATIM QUESTION: Will the FDA accept an EUA submission that leverages validation data from the CDC's EUA?
VERBATIM ANSWER: Yes, we would want you to come in with an EUA request for your test. But you could in your EUA request reference the CDC EUA so you would not have to repeat the validation that they have in their EUA. We could leverage that.
SPEAKER QUESTION: BJ Tatel
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submissions, CDC EUA data, FDA validation requirements
REVIEW FLAG: False

QA Block 5-10
CLARIFIED QUESTION: What components (e.g., primers, probes, reagents) are required to independently validate a test based on the CDC template?
CLARIFIED ANSWER: To independently validate a test based on the CDC template, you must secure your own primers, probes, and reagents and conduct the validation process yourself.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So if you follow that pathway you would do your own validation of that test. And then Toby is there, you know, you would you would order your own primers and probes and reagents and validate it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC assay validation, Test components
REVIEW FLAG: False

QA Block 5-11
CLARIFIED QUESTION: Are there specific guidelines for ordering materials like primers and probes for validation?
CLARIFIED ANSWER: Laboratories should order their own primers, probes, and reagents and perform validation of the test themselves.
VERBATIM QUESTION: Are there specific guidelines for ordering materials like primers and probes for validation?
VERBATIM ANSWER: So if you follow that pathway you would do your own validation of that test. And then Toby is there, you know, you would you would order your own primers and probes and reagents and validate it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: primers and probes, validation requirements
REVIEW FLAG: False


#### 6. Guidelines for Enriching Populations in Antigen Test Studies

QA Block 6-1
CLARIFIED QUESTION: Can the population be enriched to include those who test positive in either the non-laboratory or a healthcare setting?
CLARIFIED ANSWER: Yes, the FDA considers it reasonable to enrich the population for those testing positive in non-laboratory or healthcare settings, but it depends on the methodology used. FDA suggests discussing specifics with their antigen team, and they plan to update the template accordingly.
VERBATIM QUESTION: Can the population be enriched to include those who test positive in either the non-laboratory or a healthcare setting?
VERBATIM ANSWER: Yes, we would - if you can send that question in so that you can talk with our antigen team about it, that would be the best step. Generally yes, we would consider that to be a reasonable approach but we would want to discuss the way that you're doing it. And we will most likely be updating the antigen template to include information on that.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: population enrichment, antigen test templates, study design
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Are there limitations to the assays that can be used to confirm a positive case when enriching the population?
CLARIFIED ANSWER: FDA recommends using a high sensitivity PCR test as a comparator when confirming a positive case, but suggests discussing specifics with the antigen team.
VERBATIM QUESTION: Are there limitations to the assays that can be used to confirm a positive case when enriching the population?
VERBATIM ANSWER: I think that probably would be a better question to discuss with our antigen team specifically but generally you'd want to use a high sensitivity PCR test as a comparator.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: assay limitations, PCR test, antigen enrichment
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: Will the FDA antigen template be updated to clarify enrichment processes for healthcare settings?
CLARIFIED ANSWER: The FDA is likely to update the antigen template to include information on enrichment processes for healthcare settings but recommends discussing specific approaches with their team.
VERBATIM QUESTION: Will the FDA antigen template be updated to clarify enrichment processes for healthcare settings?
VERBATIM ANSWER: Yes, we would - if you can send that question in so that you can talk with our antigen team about it, that would be the best step. Generally yes, we would consider that to be a reasonable approach but we would want to discuss the way that you're doing it. And we will most likely be updating the antigen template to include information on that.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: antigen template, enrichment processes, healthcare settings
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: Does the FDA require developers to address potential bias for visually read antigen tests as part of the study design?
CLARIFIED ANSWER: The FDA wants developers to address potential bias for visually read antigen tests, particularly as it relates to enriching studies.
VERBATIM QUESTION: Does the FDA require developers to address potential bias for visually read antigen tests as part of the study design?
VERBATIM ANSWER: And - yes and regarding enriching I know that the team also wants to consider how you're addressing bias if it's the test that's visually read.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Bias in antigen tests, Study design considerations
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Is it necessary to consult the antigen team before implementing enrichment methods in a study?
CLARIFIED ANSWER: Yes, it is recommended to consult the FDA antigen team before implementing enrichment methods. They consider it a reasonable approach generally, but input and discussion on the method are necessary.
VERBATIM QUESTION: Is it necessary to consult the antigen team before implementing enrichment methods in a study?
VERBATIM ANSWER: Yes, we would - if you can send that question in so that you can talk with our antigen team about it, that would be the best step. Generally yes, we would consider that to be a reasonable approach but we would want to discuss the way that you're doing it. And we will most likely be updating the antigen template to include information on that.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: enrichment methods, antigen team consultation, antigen template guidance
REVIEW FLAG: False


#### 7. FDA Triage and Priority System for Test Applications

QA Block 7-1
CLARIFIED QUESTION: What is the process for assigning a test submission into the triage program and how does a test submission get out of it?
CLARIFIED ANSWER: The process ensures submissions that don't require EUA or fall into high-priority categories may be placed into a program for weekly status updates. Submissions move forward based on priority and reviewer availability for an interactive review.
VERBATIM QUESTION: What is the process for assigning a test submission into the triage program and how does a test submission get out of it?
VERBATIM ANSWER: Yes, I can take a crack at that and Toby can fill in. So are our reviewers are obviously their desks and plates are very full with submissions and reviews. And in order to get through them as quickly as possible we have a program that when we receive an application we want to make sure it's not something that requires an EUA to launch that is if there's a notification pathway for the test and/or it doesn't have - it meets one of our other definitions for something that would be put into a high priority category. And then if it doesn't meet any of those categories and perhaps even if it does if our reviewers' plates are full, there is a triage program or I wouldn't call it triage. There's just a program that puts applications with somebody who can keep in contact with the developer and give them a status update at least on a weekly basis as to where their application is in the process. And as soon as a space opens up on reviewers' plates then we put in those submissions based on the kinds of priorities that I discussed onto the next open reviewers' slot that they are carrying a number of applications all at once and then the beginning of a true interactive review can happen. So typically those happen for tests that can be launched through the notification pathway prior to an EUA authorization.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: triage program, test submission prioritization, EUA and notifications
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: Is the prioritization based on CDC categorization of how a test will be used or by some other method?
CLARIFIED ANSWER: Prioritization is based on whether a test is for point-of-care use, which requires EUA authorization, making it a higher priority.
VERBATIM QUESTION: Is the prioritization based on CDC categorization of how a test will be used or by some other method?
VERBATIM ANSWER: So, you know, anything that's the point of care if it's truly going to be used at point of care does require an EUA authorization to deem it as CLIA waived or non-lab or home collection situations. So those all require EUAs and so they aren't allowed to launch for those indications until they have that EUA authorization. So those are the ones in greatest need to be able to offer that test in the US. So those and those do get a higher priority because of that requirement. So if all the point of care test information is in the application for the reviewer to review then they would receive - that would receive a higher priority in our review process because they can't notify and launch point of care.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care prioritization, EUA authorization, Test review process
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: Does a point of care test, especially a rapid test, receive higher priority than a test that can be launched in a high complexity lab?
CLARIFIED ANSWER: Yes, point of care tests, especially rapid tests, receive higher priority if they require authorization for use in specific settings and cannot simply be used in a high complexity lab.
VERBATIM QUESTION: Does a point of care test, especially a rapid test, receive higher priority than a test that can be launched in a high complexity lab?
VERBATIM ANSWER: Yes. And if you come in with something that that truly does, you know, with data that does require an authorization to be in that particular patient or consumer setting then - and can't just be performed in a high complexity lab, then that would automatically be a higher priority.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: priority review criteria, point of care testing, EUA authorization
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: What constitutes a high-priority category for COVID-19 diagnostic test submissions?
CLARIFIED ANSWER: Point-of-care tests, including rapid tests, that require EUA authorization for CLIA waiver, non-lab, or home collection receive the highest priority because they cannot launch without authorization.
VERBATIM QUESTION: What constitutes a high-priority category for COVID-19 diagnostic test submissions?
VERBATIM ANSWER: So, you know, anything that's the point of care if it's truly going to be used at point of care does require an EUA authorization to deem it as CLIA waived or non-lab or home collection situations. So those all require EUAs and so they aren't allowed to launch for those indications until they have that EUA authorization. So those are the ones in greatest need to be able to offer that test in the US. So those and those do get a higher priority because of that requirement. So if all the point of care test information is in the application for the reviewer to review then they would receive - that would receive a higher priority in our review process because they can't notify and launch point of care.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: High-priority test categories, Point-of-care tests, EUA authorization
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: How does the notification pathway differ from the EUA authorization process in terms of eligibility to launch a test?
CLARIFIED ANSWER: Point-of-care tests require an EUA authorization to be launched for CLIA waivers, non-labs, or home collections, as they can't launch via notification alone, making them higher priority.
VERBATIM QUESTION: How does the notification pathway differ from the EUA authorization process in terms of eligibility to launch a test?
VERBATIM ANSWER: So, you know, anything that's the point of care if it's truly going to be used at point of care does require an EUA authorization to deem it as CLIA waived or non-lab or home collection situations. So those all require EUAs and so they aren't allowed to launch for those indications until they have that EUA authorization. So those are the ones in greatest need to be able to offer that test in the US. So those and those do get a higher priority because of that requirement. So if all the point of care test information is in the application for the reviewer to review then they would receive - that would receive a higher priority in our review process because they can't notify and launch point of care.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: notification pathway, EUA authorization, priority testing
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: What kind of status updates should a developer expect when their application is placed into the secondary program (triage program replacement)?
CLARIFIED ANSWER: The FDA assigns someone to provide weekly status updates to developers about where their application is in the process. Once reviewer availability opens up, submissions are assigned based on priority for interactive review.
VERBATIM QUESTION: What kind of status updates should a developer expect when their application is placed into the secondary program (triage program replacement)?
VERBATIM ANSWER: There's just a program that puts applications with somebody who can keep in contact with the developer and give them a status update at least on a weekly basis as to where their application is in the process. And as soon as a space opens up on reviewers' plates then we put in those submissions based on the kinds of priorities that I discussed onto the next open reviewers' slot that they are carrying a number of applications all at once and then the beginning of a true interactive review can happen.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: status updates, triage program process, application review timeline
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: What specific information is required for a point-of-care test application to ensure prioritization under the review process?
CLARIFIED ANSWER: Point-of-care tests need EUA authorization to be classified as CLIA-waived or used in non-lab/home settings. Applications containing all required information for review receive higher prioritization since these tests cannot launch through notification alone.
VERBATIM QUESTION: What specific information is required for a point-of-care test application to ensure prioritization under the review process?
VERBATIM ANSWER: So, you know, anything that's the point of care if it's truly going to be used at point of care does require an EUA authorization to deem it as CLIA waived or non-lab or home collection situations. So those all require EUAs and so they aren't allowed to launch for those indications until they have that EUA authorization. So those are the ones in greatest need to be able to offer that test in the US. So those and those do get a higher priority because of that requirement. So if all the point of care test information is in the application for the reviewer to review then they would receive - that would receive a higher priority in our review process because they can't notify and launch point of care.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care test prioritization, EUA authorization requirements, Review process
REVIEW FLAG: False


#### 8. Serology Testing: Sample Collection and Transport Guidelines

QA Block 8-1
CLARIFIED QUESTION: Does a serology test using blood as a sample require the person taking the sample to be a lab employee, or can it be a phlebotomist or clinician?
CLARIFIED ANSWER: A serology test using blood can have the sample collected by a phlebotomist or clinician elsewhere if the test and sample type are authorized, and the testing is performed in an FDA-authorized high complexity lab.
VERBATIM QUESTION: Does a serology test using blood as a sample require the person taking the sample to be a lab employee, or can it be a phlebotomist or clinician?
VERBATIM ANSWER: As far as transporting and collecting somewhere else, transporting a serum plasma or whole blood sample if the test has been authorized for those sample types to a lab setting that has been authorized or allowed by our guidance in the notification process which in most cases of course is a high complexity lab, the testing can then be performed with that sample collected somewhere else in the high complexity lab.
SPEAKER QUESTION: David Adams
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology tests, sample collection requirements, high complexity labs
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: What are the requirements if a serology test uses whole blood from a blood draw?
CLARIFIED ANSWER: If a serology test uses whole blood from a blood draw, the sample must be collected and transported to a lab setting authorized under FDA guidance, usually a high-complexity lab, where the test will be performed.
VERBATIM QUESTION: What are the requirements if a serology test uses whole blood from a blood draw?
VERBATIM ANSWER: But as far as transporting and collecting somewhere else, transporting a serum plasma or whole blood sample if the test has been authorized for those sample types to a lab setting that has been authorized or allowed by our guidance in the notification process which in most cases of course is a high complexity lab, the testing can then be performed with that sample collected somewhere else in the high complexity lab.
SPEAKER QUESTION: David Adams
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test requirements, Whole blood processing, Lab authorization
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: What are the requirements if a serology test uses a finger-stick sample?
CLARIFIED ANSWER: The FDA has not authorized a finger-stick method for transporting samples under EUA. Transporting and testing of serum, plasma, or whole blood is permitted when authorized and performed in a high-complexity lab.
VERBATIM QUESTION: What are the requirements if a serology test uses a finger-stick sample?
VERBATIM ANSWER: So a finger stick is something that I don't believe we have authorized sort of a finger stick method in an EUA authorization where you could transport that with a device. I don't - and Toby you can correct me, I don't think we have. But as far as transporting and collecting somewhere else, transporting a serum plasma or whole blood sample if the test has been authorized for those sample types to a lab setting that has been authorized or allowed by our guidance in the notification process which in most cases of course is a high complexity lab, the testing can then be performed with that sample collected somewhere else in the high complexity lab.
SPEAKER QUESTION: David Adams
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Finger-stick requirements, Sample transport, EUA for serology tests
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: Is a finger-stick method authorized under an EUA for transporting the sample with a device?
CLARIFIED ANSWER: FDA has not authorized a finger-stick method under an EUA where the sample can be transported with a device.
VERBATIM QUESTION: Is a finger-stick method authorized under an EUA for transporting the sample with a device?
VERBATIM ANSWER: So a finger stick is something that I don't believe we have authorized sort of a finger stick method in an EUA authorization where you could transport that with a device.
SPEAKER QUESTION: David Adams
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: finger-stick method, EUA, sample transport
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Can whole blood, serum, or plasma samples collected off-site be tested in a high-complexity lab if the test is authorized for those sample types?
CLARIFIED ANSWER: Yes, serum, plasma, or whole blood samples collected off-site can be tested in a high-complexity lab if the test is authorized for those sample types and aligns with FDA guidance.
VERBATIM QUESTION: Can whole blood, serum, or plasma samples collected off-site be tested in a high-complexity lab if the test is authorized for those sample types?
VERBATIM ANSWER: But as far as transporting and collecting somewhere else, transporting a serum plasma or whole blood sample if the test has been authorized for those sample types to a lab setting that has been authorized or allowed by our guidance in the notification process which in most cases of course is a high complexity lab, the testing can then be performed with that sample collected somewhere else in the high complexity lab.
SPEAKER QUESTION: David Adams
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample testing in high-complexity labs, authorized tests for sample types, FDA guidance
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: Does the notification process allow for transporting collected blood samples to high-complexity labs for testing?
CLARIFIED ANSWER: Blood samples, including serum, plasma, or whole blood, can be transported to high-complexity labs for testing if the test is authorized for those sample types under the notification process.
VERBATIM QUESTION: Does the notification process allow for transporting collected blood samples to high-complexity labs for testing?
VERBATIM ANSWER: As far as transporting and collecting somewhere else, transporting a serum plasma or whole blood sample if the test has been authorized for those sample types to a lab setting that has been authorized or allowed by our guidance in the notification process which in most cases of course is a high complexity lab, the testing can then be performed with that sample collected somewhere else in the high complexity lab.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: blood sample transport, high-complexity lab testing, notification process
REVIEW FLAG: False


#### 9. Requirements for Specimen Collection and Personnel Qualifications

QA Block 9-1
CLARIFIED QUESTION: What are the state-specific regulations regarding specimen collection for COVID-19 testing compared to federal CLIA requirements?
CLARIFIED ANSWER: The federal CLIA regulations generally do not require a certificate for specimen collection-only sites staffed by non-laboratory personnel, but some states may enforce stricter rules. Specimen collection is typically performed by state-licensed individuals trained in patient care but not necessarily in laboratory testing.
VERBATIM QUESTION: What are the state-specific regulations regarding specimen collection for COVID-19 testing compared to federal CLIA requirements?
VERBATIM ANSWER: My understanding from my colleagues at CMS is that CLIA generally does not require a CLIA certificate for a specimen collection only site. So at the collection site that does not need to fall under the laboratory and does not need to be staffed by lab personnel. Although I believe that some states may have more strict interpretations than the federal CLIA regulation. But generally when we are referring to, you know, healthcare provider observed or directed or performed specimen collection as we've noted on a number of authorizations we would we would expect that that individual be someone who, you know, is generally trained in patient care but not necessarily trained in laboratory testing. But it would, you know, be someone who is licensed by whatever state or the local laws are necessary for specimen collection.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA and specimen collection, State versus federal regulations, COVID-19 testing requirements
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Does a specimen collection-only site need to be staffed by personnel with laboratory-specific training?
CLARIFIED ANSWER: CLIA does not generally require a specimen collection-only site to have lab-trained staff; however, some states may have stricter regulations. Individuals collecting specimens should be licensed and trained in patient care, not necessarily in lab testing, as per state or local requirements.
VERBATIM QUESTION: Does a specimen collection-only site need to be staffed by personnel with laboratory-specific training?
VERBATIM ANSWER: My understanding from my colleagues at CMS is that CLIA generally does not require a CLIA certificate for a specimen collection only site. So at the collection site that does not need to fall under the laboratory and does not need to be staffed by lab personnel. Although I believe that some states may have more strict interpretations than the federal CLIA regulation. But generally when we are referring to, you know, healthcare provider observed or directed or performed specimen collection as we've noted on a number of authorizations we would we would expect that that individual be someone who, you know, is generally trained in patient care but not necessarily trained in laboratory testing. But it would, you know, be someone who is licensed by whatever state or the local laws are necessary for specimen collection.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA regulations, specimen collection, staff qualifications
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: What level of training or licensure is required for individuals performing healthcare provider-observed specimen collection?
CLARIFIED ANSWER: CLIA does not require certification for specimen collection sites, and staff do not need to be lab personnel. However, individuals performing healthcare provider-observed collection should be generally trained in patient care and licensed per state or local laws.
VERBATIM QUESTION: What level of training or licensure is required for individuals performing healthcare provider-observed specimen collection?
VERBATIM ANSWER: My understanding from my colleagues at CMS is that CLIA generally does not require a CLIA certificate for a specimen collection only site. So at the collection site that does not need to fall under the laboratory and does not need to be staffed by lab personnel. Although I believe that some states may have more strict interpretations than the federal CLIA regulation. But generally when we are referring to, you know, healthcare provider observed or directed or performed specimen collection as we've noted on a number of authorizations we would we would expect that that individual be someone who, you know, is generally trained in patient care but not necessarily trained in laboratory testing. But it would, you know, be someone who is licensed by whatever state or the local laws are necessary for specimen collection.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: licensure for specimen collection, CLIA requirements, state law variations
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: Is specimen collection for COVID-19 diagnostics under the FDA's regulatory purview?
CLARIFIED ANSWER: Specimen collection is generally not under FDA's purview unless explicitly specified. Checking with CMS, CLIA, and state or local officials is recommended.
VERBATIM QUESTION: Is specimen collection for COVID-19 diagnostics under the FDA's regulatory purview?
VERBATIM ANSWER: So from an FDA perspective, things should be clear from our - from the, you know, from the instructions for use that the testing is performed in the right setting. But sample collection is not so much unless we specify it under our purview. And so, you know, also perhaps going to CMS and checking on this would  or CLIA, would be and your state and local officials would be a good place also to check.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: specimen collection, FDA regulatory purview, CLIA and CMS guidance
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: Should developers consult CMS or CLIA about requirements for specimen collection at non-laboratory sites?
CLARIFIED ANSWER: Developers should consult CMS, CLIA, and state or local officials about requirements for specimen collection at non-laboratory sites since FDA generally does not regulate this area unless specified.
VERBATIM QUESTION: Should developers consult CMS or CLIA about requirements for specimen collection at non-laboratory sites?
VERBATIM ANSWER: So from an FDA perspective, things should be clear from our - from the, you know, from the instructions for use that the testing is performed in the right setting. But sample collection is not so much unless we specify it under our purview. And so, you know, also perhaps going to CMS and checking on this would  or CLIA, would be and your state and local officials would be a good place also to check.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: specimen collection, regulatory agencies, developer guidance
REVIEW FLAG: False


#### 10. Challenges and Validation of Saliva-Based COVID-19 Testing

QA Block 10-1
CLARIFIED QUESTION: How did the Yale team and others address the issue of inconsistencies with saliva in direct antigen tests?
CLARIFIED ANSWER: FDA acknowledges challenges with saliva inconsistencies in direct antigen tests due to variability in performance compared to nasopharyngeal or mid-turbinate swabs. Despite limited understanding, FDA has authorized multiple methods and expects further authorizations for saliva testing in expanded testing scenarios.
VERBATIM QUESTION: How did the Yale team and others address the issue of inconsistencies with saliva in direct antigen tests?
VERBATIM ANSWER: And so we continue to have cautions about saliva. The - and we have not been able to authorize some or that - or some that we're willing to authorize have limitations because the performance comparison to the ideal recommended sample type which is a nasopharyngeal swab. We'll also be open to a mid-turbinate swab. We found if the studies don't FDA Webinar compare to those two that we can - we're unclear of the actual performance because saliva being such a unique respiratory sample type and having issues that frankly that we don't fully understand the science around about why there is such variability. Now very clearly there's been a lot of different sort of methods that we've authorized and we think that more will be coming as well using saliva because when we're, you know, we're cautious we realize that saliva is a very important sample type especially as have we've greatly expanded testing.
SPEAKER QUESTION: Louis Perlmutter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva inconsistencies, direct antigen tests, FDA authorizations
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Where can I find the EUA-accepted tests on the FDA website?
CLARIFIED ANSWER: You can find a list of EUA-authorized tests on the FDA's In Vitro Diagnostics EUA webpage, which includes details about authorizations, studies, and results.
VERBATIM QUESTION: Where can I find the EUA-accepted tests on the FDA website?
VERBATIM ANSWER: So we do have an In vitro Diagnostics EUA Web page at the FDA so that you can search on those terms. I don't know if the slide deck has a link to this or not that's been shared with participants today. Okay, okay. And so that's where you can, you know, find all the information on what's authorized and what studies were done and what the results of those studies are. So it's either depending on whether it's a kit manufacturer or not it's either called an IFU, Instructions for Use on EUA Summary and in all the information is in there.
SPEAKER QUESTION: Louis Perlmutter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA-authorized tests, FDA webpage, Instructions for Use (IFU)
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What is the FDA's recommended comparator sample type for validating saliva as a respiratory sample in COVID-19 tests?
CLARIFIED ANSWER: The FDA recommends using a nasopharyngeal or mid-turbinate swab as the comparator when validating saliva as a respiratory sample for COVID-19 tests, ensuring a good distribution of virus levels.
VERBATIM QUESTION: What is the FDA's recommended comparator sample type for validating saliva as a respiratory sample in COVID-19 tests?
VERBATIM ANSWER: ...but in order to really demonstrate great performance we're asking for the comparator to be a nasopharyngeal or a mid-turbinate swab and also that a good distribution of virus levels be validated.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva validation, Comparator sample type, COVID-19 diagnostic tests
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: Why does the FDA have ongoing concerns about saliva as a sample type for COVID-19 testing?
CLARIFIED ANSWER: The FDA has concerns about saliva due to its variability and unclear performance compared to recommended sample types like nasopharyngeal or mid-turbinate swabs, and the underlying science behind the variability is not fully understood.
VERBATIM QUESTION: Why does the FDA have ongoing concerns about saliva as a sample type for COVID-19 testing?
VERBATIM ANSWER: And so we continue to have cautions about saliva. The - and we have not been able to authorize some or that - or some that we're willing to authorize have limitations because the performance comparison to the ideal recommended sample type which is a nasopharyngeal swab. We'll also be open to a mid-turbinate swab. We found if the studies don't FDA Webinar compare to those two that we can - we're unclear of the actual performance because saliva being such a unique respiratory sample type and having issues that frankly that we don't fully understand the science around about why there is such variability.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva sample concerns, Variability in performance, Comparison to swab samples
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: What are the specific circumstances under which a lab does not need to submit EUA data for validation of saliva use?
CLARIFIED ANSWER: Labs with an already authorized EUA test can validate saliva use without an EUA submission if the saliva is collected in a healthcare facility under observation. EUAs are required only for home collection or other non-healthcare settings.
VERBATIM QUESTION: What are the specific circumstances under which a lab does not need to submit EUA data for validation of saliva use?
VERBATIM ANSWER: ...if you're a lab and you already have an EUA authorized test, either your lab test or a kit that you're using, you can, the lab can validate saliva without an EUA submission. It's only if you're going to go into the home collection type situation that - and other non-lab non-health care setting collection where EUAs is required for that particular purpose. But if it's going to be collected in a healthcare facility under an observation...you know, then you don't need to submit. The lab that's doing that doesn't need to submit that data to the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA data submission for saliva, Saliva validation conditions
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: What are the FDA recommendations on the distribution of viral load ranges needed for saliva test validation?
CLARIFIED ANSWER: The FDA recommends using a normal distribution of viral loads, from high to low, as measured by swab samples when validating saliva tests. Overloading with exclusively high or very low viral loads could distort performance evaluation.
VERBATIM QUESTION: What are the FDA recommendations on the distribution of viral load ranges needed for saliva test validation?
VERBATIM ANSWER: ...and it's putting pressure on swabs and transport media. And so we absolutely see utility in using saliva. So the recommendations we make when attempting to validate saliva and if you've already - if you're a lab and you already have an EUA authorized test, either your lab test or a kit that you're using, you can, the lab can validate saliva without an EUA submission. It's only if you're going to go into the home collection type situation that - and other non-lab non-health care setting collection where EUAs is required for that particular purpose. But if it's going to be collected in a healthcare facility under an observation...you know, then you don't need to submit. The lab that's doing that doesn't need to submit that data to the FDA. We welcome submissions but it's not required and it's - but in order to really demonstrate great performance we're asking for the comparator to be a nasopharyngeal or a mid-turbinate swab and also that a good distribution of virus levels be validated. So...for example if you were to load everything up with very high viral load samples...as measured by the swab that would that would tend to overestimate the performance of saliva portion of the test. and vice versa you don't want to overestimate very, very low positives because that puts the saliva sample type at jeopardy of not meeting an expected performance. So, you know, a good a normal sort of distribution from high viral load to low viral load on the swab sample is the way to go ahead and validate saliva.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva test validation, viral load distribution, FDA recommendations
REVIEW FLAG: False

QA Block 10-7
CLARIFIED QUESTION: How could overloading viral load samples at either extreme of the spectrum affect saliva test validation performance?
CLARIFIED ANSWER: Overloading with high viral load samples could overestimate saliva test performance, while overloading with very low positives could lead to insufficient performance validation. A balanced range of viral loads is recommended for accurate saliva test validation.
VERBATIM QUESTION: How could overloading viral load samples at either extreme of the spectrum affect saliva test validation performance?
VERBATIM ANSWER: ...for example if you were to load everything up with very high viral load samples as measured by the swab that would that would tend to overestimate the performance of saliva portion of the test. and vice versa you don't want to overestimate very, very low positives because that puts the saliva sample type at jeopardy of not meeting an expected performance. So, you know, a good a normal sort of distribution from high viral load to low viral load on the swab sample is the way to go ahead and validate saliva.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva test validation, viral load distribution, test performance
REVIEW FLAG: False

QA Block 10-8
CLARIFIED QUESTION: Is it necessary to submit validation data for saliva if samples are collected in a healthcare facility under supervision?
CLARIFIED ANSWER: Validation data submission for saliva is not required if samples are collected in a healthcare facility under supervision. Submission is only needed for home collection or non-healthcare settings.
VERBATIM QUESTION: Is it necessary to submit validation data for saliva if samples are collected in a healthcare facility under supervision?
VERBATIM ANSWER: It's only if you're going to go into the home collection type situation that - and other non-lab non-health care setting collection where EUAs is required for that particular purpose. But if it's going to be collected in a healthcare facility under an observation, you know, then you don't need to submit. The lab that's doing that doesn't need to submit that data to the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva sample validation, Healthcare facility supervision, EUA submission requirements
REVIEW FLAG: False


#### 11. Defining Point of Care Test Requirements and Validation

QA Block 11-1
CLARIFIED QUESTION: How does the FDA determine complexity for a point of care test to deem it sufficient for point of care designation?
CLARIFIED ANSWER: The FDA determines the complexity of point of care tests by ensuring they are easy to perform by non-laboratorians in a CLIA-waived setting using basic equipment. Simplicity, accuracy, and interpretation are key factors. Additionally, the FDA authorizes devices under CLIA-waived status during EUA reviews but makes the final formal categorization later through a normal submission process. Devices need sufficient validation to show they can be accurately performed under expected conditions.
VERBATIM QUESTION: How does the FDA determine complexity for a point of care test to deem it sufficient for point of care designation?
VERBATIM ANSWER: Yes so at a high level just to, you know, establish a baseline of understanding here, a point of care test should be easy to perform in a CLIA waived lab - a CLIA waived setting by non-laboratorians right, so anything that may require say precision pipetting or more advanced equipment that's not usually present or can't be provided in that setting. It - so it should be easy to perform. It should be something that also gives accurate results that can be easily read and easily interpreted okay? And it does loosely - we do loosely if that - now, you know, consider the point of care checklist that you referred to. But one thing to make clear is that we are not - we are deeming the CLIA waived status with authorizations. We are not making a final CLIA waiver decision or CLIA category decision for a particular device. Once that device is converted to a normal submission and we make a decision through the normal 510k de novo pathways then the formal CLIA categorization will be applied to that. One of the reasons for that is that we are - the bar here for sufficient clinical testing and performance is so much lower than our normal bar. And we want to make sure that when we make that final decision on the final device at conversion meets our CLIA performance considerations. So if you look at what we've authorized already, some of them were on instruments that we have previously waived. And as long as the workflow hasn't changed that would introduce any more challenges to the point of care setting, we have not required additional point of care studies. It's - but a device that has never been waived prior to the pandemic. We are asking for some very, you know, less - a lower bar as far as the amount of FDA Webinar validation goes for the CLIA waived setting to show that it can be easily and accurately performed and interpreted. And that includes any steps that there are - that there's appropriate guard band studies I call them but basically flex studies that look at if you shift time of reading, time of incubations beyond the package insert what is the what is the effect on result.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA waiver process, Point of care validation, FDA criteria for tests
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Are certain assay types more difficult to make a point of care case for than others?
CLARIFIED ANSWER: Certain assay types are more challenging for point of care due to complexity, like tests requiring precision pipetting or advanced equipment. FDA's standards for point of care tests are reduced compared to typical lab diagnostics to ensure accuracy and ease of use in simpler settings.
VERBATIM QUESTION: Are certain assay types more difficult to make a point of care case for than others?
VERBATIM ANSWER: Yes so at a high level just to, you know, establish a baseline of understanding here, a point of care test should be easy to perform in a CLIA waived lab - a CLIA waived setting by non-laboratorians right, so anything that may require say precision pipetting or more advanced equipment that's not usually present or can't be provided in that setting. It - so it should be easy to perform. It should be something that also gives accurate results that can be easily read and easily interpreted okay? And it does loosely - we do loosely if that - now, you know, consider the point of care checklist that you referred to. But one thing to make clear is that we are not - we are deeming the CLIA waived status with authorizations. We are not making a final CLIA waiver decision or CLIA category decision for a particular device. Once that device is converted to a normal submission and we make a decision through the normal 510k de novo pathways then the formal CLIA categorization will be applied to that. One of the reasons for that is that we are - the bar here for sufficient clinical testing and performance is so much lower than our normal bar. And we want to make sure that when we make that final decision on the final device at conversion meets our CLIA performance considerations. So if you look at what we've authorized already, some of them were on instruments that we have previously waived. And as long as the workflow hasn't changed that would introduce any more challenges to the point of care setting, we have not required additional point of care studies.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point of care assay complexity, CLIA categorization, FDA standards for testing
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: Would the FDA consider a 96 well plate-based assay for point of care testing if it met the criteria?
CLARIFIED ANSWER: The FDA noted that 96 well plate assays often involve precision steps unsuitable for non-laboratorians and may be prone to contamination. However, they remain open to evaluating specific tests, though such point of care assays are challenging to develop.
VERBATIM QUESTION: Would the FDA consider a 96 well plate-based assay for point of care testing if it met the criteria?
VERBATIM ANSWER: Yes. So something that involves a 96 well plate usually involves precision typesetting something that a non-laboratorian would not be trained in. And I'm not going to say, you know, no until we see more details about a specific test. But it would be very challenging. Those lab environments are not set up to prevent cross-contamination, monitoring contamination -- things like that. So typically these point of care assays need to be self-contained so that disposal is easy and doesn't result in contaminating the work area where the testing is performed. So I'd encourage you to come in with some ideas, absolutely interested in point of care. They are - I have had experience developing point of care devices. They are and getting moved to the FDA. And they are before I joined the FDA and they are a bit more challenging to develop. We understand that. But you will see you will see more and more point of care tests authorized in this pandemic and hopefully in the near future that don't require instrumentation.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 96 well plate assays, Point of care testing, FDA criteria
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: Is the bar higher in terms of validation for a test to qualify as point of care compared to a lab-based assay or is it comparable or lower?
CLARIFIED ANSWER: The FDA has lowered the bar for point-of-care diagnostic devices compared to central lab tests, allowing for reduced sensitivity (e.g., 80% PPA for direct antigen tests) to prioritize rapid identification of high viral load or symptomatic patients.
VERBATIM QUESTION: Is the bar higher in terms of validation for a test to qualify as point of care compared to a lab-based assay or is it comparable or lower?
VERBATIM ANSWER: The percent positive agreement or sensitivity and specificities are basically the same that we would allow - we have authorized the direct antigen test. Some of them at least initially were say at the 80% PPA or sensitivity mark in carry. And some of them I think still do carry a presumed negative claim. So, you know, we typically we think of a central lab saying molecular test as being able to do much better than an 80% PPA or sensitivity. But we do - we FDA Webinar have lowered the bar to these point of care devices as I mentioned sort of in the beginning of this call. If it's down to 80% for a point of care say direct antigen test and a molecular test we would authorize as well but there would be a limitation that the negatives might not really be negative. And so we have lowered the bar relative to what normally people think of as a central lab test. And one of the reasons for that is identifying this population of patients that have very high viral loads that are likely to be infectious or they're symptomatic and you want to know right away in a point of care center setting do they, you know, are they positive?
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation standards for diagnostics, Point-of-care tests, Comparison with lab-based assays
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: What are the specific requirements for performing guard band or flex studies for point of care tests?
CLARIFIED ANSWER: Guard band or flex studies evaluate the effects of changes in time of reading or incubations beyond the instructions on the test results.
VERBATIM QUESTION: What are the specific requirements for performing guard band or flex studies for point of care tests?
VERBATIM ANSWER: And that includes any steps that there are - that there's appropriate guard band studies I call them but basically flex studies that look at if you shift time of reading, time of incubations beyond the package insert what is the what is the effect on result.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: guard band/flex studies, point of care tests
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: Can devices that were previously CLIA-waived skip additional point of care studies if their workflows remain unchanged?
CLARIFIED ANSWER: The FDA does not require additional point-of-care studies for previously CLIA-waived devices if their workflows remain unchanged in a way that could affect ease of use or result interpretation.
VERBATIM QUESTION: Can devices that were previously CLIA-waived skip additional point of care studies if their workflows remain unchanged?
VERBATIM ANSWER: So if you look at what we've authorized already, some of them were on instruments that we have previously waived. And as long as the workflow hasn't changed that would introduce any more challenges to the point of care setting, we have not required additional point of care studies.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA-waived devices, Point-of-care studies, Workflow impact
REVIEW FLAG: False

QA Block 11-7
CLARIFIED QUESTION: What are the FDA's requirements for devices seeking point of care authorization to demonstrate they are easy to perform by non-laboratorians?
CLARIFIED ANSWER: Point of care tests must be easy to perform in a CLIA-waived setting by non-laboratorians, without requiring precision pipetting or advanced equipment. They should also provide accurate, easily read, and interpreted results. The FDA considers a lower bar for clinical testing during EUA authorization but applies formal CLIA categorization after full review.
VERBATIM QUESTION: What are the FDA's requirements for devices seeking point of care authorization to demonstrate they are easy to perform by non-laboratorians?
VERBATIM ANSWER: Yes so at a high level just to, you know, establish a baseline of understanding here, a point of care test should be easy to perform in a CLIA waived lab - a CLIA waived setting by non-laboratorians right, so anything that may require say precision pipetting or more advanced equipment that's not usually present or can't be provided in that setting. It - so it should be easy to perform. It should be something that also gives accurate results that can be easily read and easily interpreted okay? And it does loosely - we do loosely if that - now, you know, consider the point of care checklist that you referred to. But one thing to make clear is that we are not - we are deeming the CLIA waived status with authorizations. We are not making a final CLIA waiver decision or CLIA category decision for a particular device. Once that device is converted to a normal submission and we make a decision through the normal 510k de novo pathways then the formal CLIA categorization will be applied to that. One of the reasons for that is that we are - the bar here for sufficient clinical testing and performance is so much lower than our normal bar. And we want to make sure that when we make that final decision on the final device at conversion meets our CLIA performance considerations.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point of care test requirements, device authorization, CLIA waiver
REVIEW FLAG: False

QA Block 11-8
CLARIFIED QUESTION: How does the FDA evaluate instruments that have not been waived prior to the pandemic for point of care testing?
CLARIFIED ANSWER: The FDA uses a lower bar for validation of devices that have not been waived prior to the pandemic, focusing on whether they can be easily and accurately performed and interpreted in a CLIA-waived setting. This includes conducting guard band or flex studies to assess the impact of timing variations.
VERBATIM QUESTION: How does the FDA evaluate instruments that have not been waived prior to the pandemic for point of care testing?
VERBATIM ANSWER: It's - but a device that has never been waived prior to the pandemic. We are asking for some very, you know, less - a lower bar as far as the amount of FDA Webinar validation goes for the CLIA waived setting to show that it can be easily and accurately performed and interpreted. And that includes any steps that there are - that there's appropriate guard band studies I call them but basically flex studies that look at if you shift time of reading, time of incubations beyond the package insert what is the what is the effect on result. So hopefully that's helpful.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA evaluation, CLIA-waived instruments, Validation requirements
REVIEW FLAG: False

QA Block 11-9
CLARIFIED QUESTION: What criteria does the FDA use during the EUA review process to determine if a device qualifies for point of care testing?
CLARIFIED ANSWER: The FDA considers whether the test can be easily performed in a CLIA waived setting by non-laboratorians, provides accurate and interpretable results, and aligns with a looser consideration of the point of care checklist. However, full CLIA categorization is deferred until a formal submission through the 510(k) or de novo path. Clinical testing requirements for EUA are less stringent than for final approvals.
VERBATIM QUESTION: What criteria does the FDA use during the EUA review process to determine if a device qualifies for point of care testing?
VERBATIM ANSWER: Yes so at a high level just to, you know, establish a baseline of understanding here, a point of care test should be easy to perform in a CLIA waived lab - a CLIA waived setting by non-laboratorians right, so anything that may require say precision pipetting or more advanced equipment that's not usually present or can't be provided in that setting. It - so it should be easy to perform. It should be something that also gives accurate results that can be easily read and easily interpreted okay? And it does loosely - we do loosely if that - now, you know, consider the point of care checklist that you referred to. But one thing to make clear is that we are not - we are deeming the CLIA waived status with authorizations. We are not making a final CLIA waiver decision or CLIA category decision for a particular device. Once that device is converted to a normal submission and we make a decision through the normal 510k de novo pathways then the formal CLIA categorization will be applied to that. One of the reasons for that is that we are - the bar here for sufficient clinical testing and performance is so much lower than our normal bar. And we want to make sure that when we make that final decision on the final device at conversion meets our CLIA performance considerations. So if you look at what we've authorized already, some of them were on instruments that we have previously waived. And as long as the workflow hasn't changed that would introduce any more challenges to the point of care setting, we have not required additional point of care studies. It's - but a device that has never been waived prior to the pandemic. We are asking for some very, you know, less - a lower bar as far as the amount of FDA Webinar validation goes for the CLIA waived setting to show that it can be easily and accurately performed and interpreted. And that includes any steps that there are - that there's appropriate guard band studies I call them but basically flex studies that look at if you shift time of reading, time of incubations beyond the package insert what is the what is the effect on result. So hopefully that's helpful. Those who are seeking point of care tests here we - you can come in with the pre EUA and ask specific questions about whether your device, you know, in development would potentially meet the criteria for that. And then of course we make that decision during the formal EUA review process.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA criteria, Point of care testing, CLIA categorization
REVIEW FLAG: False

QA Block 11-10
CLARIFIED QUESTION: Under what conditions could devices that usually require laboratory settings, such as those utilizing 96-well plates, be considered for point of care authorization?
CLARIFIED ANSWER: Devices involving 96-well plates face challenges being authorized for point of care due to their reliance on precision handling and contamination risks. However, FDA recommends submitting specifics to assess feasibility.
VERBATIM QUESTION: Under what conditions could devices that usually require laboratory settings, such as those utilizing 96-well plates, be considered for point of care authorization?
VERBATIM ANSWER: Yes. So something that involves a 96 well plate usually involves precision typesetting something that a non-laboratorian would not be trained in. And I'm not going to say, you know, no until we see more details about a specific test. But it would be very challenging. Those lab environments are not set up to prevent cross-contamination, monitoring contamination -- things like that. So typically these point of care assays need to be self-contained so that disposal is easy and doesn't result in contaminating the work area where the testing is performed. So I'd encourage you to come in with some ideas, absolutely interested in point of care.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point of care devices, 96-well plate assays, Authorization challenges
REVIEW FLAG: False

QA Block 11-11
CLARIFIED QUESTION: Does the FDA prefer self-contained point of care assays to prevent contamination?
CLARIFIED ANSWER: The FDA prefers point of care assays to be self-contained to prevent cross-contamination and simplify disposal.
VERBATIM QUESTION: Does the FDA prefer self-contained point of care assays to prevent contamination?
VERBATIM ANSWER: Yes. So something that involves a 96 well plate usually involves precision typesetting something that a non-laboratorian would not be trained in. And I'm not going to say, you know, no until we see more details about a specific test. But it would be very challenging. Those lab environments are not set up to prevent cross-contamination, monitoring contamination -- things like that. So typically these point of care assays need to be self-contained so that disposal is easy and doesn't result in contaminating the work area where the testing is performed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point of Care Assays, Contamination Prevention, Assay Design
REVIEW FLAG: False


#### 12. FDA EUA Notification Process and Application Clarifications

QA Block 12-1
CLARIFIED QUESTION: Is there a limit to how long a test can be on the notification pathway without substantive review or authorization by the FDA?
CLARIFIED ANSWER: There is no limit to how long a test can remain on the notification pathway. FDA's process involves triaging applications to prioritize public health needs and addressing any risks or missing elements before advancing to review.
VERBATIM QUESTION: Is there a limit to how long a test can be on the notification pathway without substantive review or authorization by the FDA?
VERBATIM ANSWER: Well there is no limit. And what we do when we receive applications is, we have our expert review staff take a quick look at it and they do a couple of really key things when they take a good look at it. First of all does it fall into one of FDA Webinar these higher priority buckets that requires or would benefit, public health would really benefit from an authorization coming sooner than later? And then second are there any issues that we see? And that is, are there any performance characteristics, issues that would suggest there would be any sort of risk to public health? If there is that does get put into a higher priority bucket so that we can reach out to the developer and likely ask for some more information about what's going on. And, you know, and deal appropriately with the response that we get. And we have denied a number of assays that have fallen into that category already. And we maintain some of that list on our Web site. So the other thing they - we want them to do is note if there's any missing pieces to the application. And then they give that over to the assigned contact and that contact can provide that feedback to the developer. That is okay your application, you know, looks complete and we're in a holding pattern right now. And if you notified then you have confirmation of notification from us. That will happen. That doesn't have to wait on a reviewer. But also that contact can say, "Oh we took a look at it. We don't necessarily have many concerns at the moment but we noticed that you have these missing elements so that you can work on those." And those can be provided because we actually probably in most cases won't hand that application over to a reviewer until we think that the application is complete so the reviewer's making the most efficient use of their time and as rapidly as possible reaching authorization decisions for the items that are on their plate and they're not holding in holding patterns with a number of different developers. So hopefully that's helpful and answers your question.
SPEAKER QUESTION: Laura D'Angelo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: notification pathway, test review process, public health priorities
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: After submitting a test for notification, will we receive confirmation of notification if missing elements are identified by the triage reviewer, or only after the application is administratively complete?
CLARIFIED ANSWER: FDA will provide confirmation of notification and work with you if missing elements are identified. A quick review will take place after submission to address prioritization, missing elements, or public health concerns.
VERBATIM QUESTION: After submitting a test for notification, will we receive confirmation of notification if missing elements are identified by the triage reviewer, or only after the application is administratively complete?
VERBATIM ANSWER: Well if we see any elements that are missing as called out in the guidance as far as what's allowed via an allowed notification option, we would work with you on that to make sure that those things are - have been validated for example. So if there's clearly something missing like, you know, there's no - but again the notification process can happen before the submission right. So we're - this is the honor system that you notify us that you've validated your test and then you have a certain period of time to submit the EUA. Once we get it then we will do a quick review to make sure what prioritization that gets and if there are any missing elements and if there is, you know, any concerns, public health concerns okay?
SPEAKER QUESTION: Laura D'Angelo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Notification process, Missing elements, EUA review workflow
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: What criteria does the FDA use to identify high-priority applications for review?
CLARIFIED ANSWER: The FDA prioritizes applications based on their potential public health benefit, addressing performance concerns, or identifying risks to public health. Applications with missing or incomplete elements are addressed with developers before review.
VERBATIM QUESTION: What criteria does the FDA use to identify high-priority applications for review?
VERBATIM ANSWER: Well there is no limit. And what we do when we receive applications is, we have our expert review staff take a quick look at it and they do a couple of really key things when they take a good look at it. First of all does it fall into one of FDA Webinar these higher priority buckets that requires or would benefit, public health would really benefit from an authorization coming sooner than later? And then second are there any issues that we see? And that is, are there any performance characteristics, issues that would suggest there would be any sort of risk to public health? If there is that does get put into a higher priority bucket so that we can reach out to the developer and likely ask for some more information about what's going on. And, you know, and deal appropriately with the response that we get. And we have denied a number of assays that have fallen into that category already. And we maintain some of that list on our Web site.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: High-priority application criteria, Public health benefit, Application review process
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What are the key performance characteristics that might lead to an application being considered a public health risk?
CLARIFIED ANSWER: Performance characteristics indicating a public health risk include issues that necessitate additional clarification or pose significant concerns based on expert review. Such tests are prioritized for further evaluation, and some have been denied based on these risks.
VERBATIM QUESTION: What are the key performance characteristics that might lead to an application being considered a public health risk?
VERBATIM ANSWER: And then second are there any issues that we see? And that is, are there any performance characteristics, issues that would suggest there would be any sort of risk to public health? If there is that does get put into a higher priority bucket so that we can reach out to the developer and likely ask for some more information about what's going on. And, you know, and deal appropriately with the response that we get. And we have denied a number of assays that have fallen into that category already. And we maintain some of that list on our Web site.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Performance risks leading to denial, FDA prioritization based on public health risk
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: What happens if an application submitted for notification is incomplete?
CLARIFIED ANSWER: If an application is incomplete, FDA usually will not pass it to a reviewer until it is complete to ensure efficient use of the reviewer's time and faster authorization decisions.
VERBATIM QUESTION: What happens if an application submitted for notification is incomplete?
VERBATIM ANSWER: And those can be provided because we actually probably in most cases won't hand that application over to a reviewer until we think that the application is complete so the reviewer's making the most efficient use of their time and as rapidly as possible reaching authorization decisions for the items that are on their plate and they're not holding in holding patterns with a number of different developers.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Incomplete applications, FDA review process, Authorization timelines
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: Is a list of denied assays made publicly available, and how can developers find this information?
CLARIFIED ANSWER: The FDA maintains a list of denied assays on their website.
VERBATIM QUESTION: Is a list of denied assays made publicly available, and how can developers find this information?
VERBATIM ANSWER: And we have denied a number of assays that have fallen into that category already. And we maintain some of that list on our Web site.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: denied assay list, public access, developer resources
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: Can the FDA provide feedback on missing elements before an in-depth review is initiated?
CLARIFIED ANSWER: The FDA provides feedback on missing elements through an assigned contact before handing the application to a reviewer, allowing developers to address issues efficiently.
VERBATIM QUESTION: Can the FDA provide feedback on missing elements before an in-depth review is initiated?
VERBATIM ANSWER: And then they give that over to the assigned contact and that contact can provide that feedback to the developer. That is okay your application, you know, looks complete and we're in a holding pattern right now. And if you notified then you have confirmation of notification from us. That will happen. That doesn't have to wait on a reviewer. But also that contact can say, "Oh we took a look at it. We don't necessarily have many concerns at the moment but we noticed that you have these missing elements so that you can work on those." And those can be provided because we actually probably in most cases won't hand that application over to a reviewer until we think that the application is complete so the reviewer's making the most efficient use of their time and as rapidly as possible reaching authorization decisions for the items that are on their plate and they're not holding in holding patterns with a number of different developers.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA feedback process, Missing elements in applications
REVIEW FLAG: False

QA Block 12-8
CLARIFIED QUESTION: Do test developers need to explicitly specify notification in their EUA submission email to be listed as a notified test?
CLARIFIED ANSWER: Test developers must specify in their EUA request email if they are notifying to be listed as a notified test; failure to do so will result in the test not being considered notified or listed.
VERBATIM QUESTION: Do test developers need to explicitly specify notification in their EUA submission email to be listed as a notified test?
VERBATIM ANSWER: You don't need to necessarily send a separate email but you do need to specify in your email when you send in your EUA request if you are also notifying. If you do not specify that you are providing notification then we will not consider you to be a notified test and we will not put you on the list as notified tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission process, Notification specification, Test listing requirements
REVIEW FLAG: False

QA Block 12-9
CLARIFIED QUESTION: What happens after notifying the FDA about a validated test prior to EUA submission?
CLARIFIED ANSWER: After notifying the FDA that a test has been validated, the FDA will verify if any key elements are missing or if there are public health concerns. If any elements are missing, they will work with the submitter to address them. Submission of the EUA follows this process.
VERBATIM QUESTION: What happens after notifying the FDA about a validated test prior to EUA submission?
VERBATIM ANSWER: Well if we see any elements that are missing as called out in the guidance as far as what's allowed via an allowed notification option, we would work with you on that to make sure that those things are - have been validated for example. So if there's clearly something missing like, you know, there's no - but again the notification process can happen before the submission right. So we're - this is the honor system that you notify us that you've validated your test and then you have a certain period of time to submit the EUA. Once we get it then we will do a quick review to make sure what prioritization that gets and if there are any missing elements and if there is, you know, any concerns, public health concerns okay?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Notification process, EUA submission, FDA review of tests
REVIEW FLAG: False

QA Block 12-10
CLARIFIED QUESTION: For applications deemed incomplete, is there a standard approach to working with the FDA to address missing elements?
CLARIFIED ANSWER: The FDA will assign a contact to provide feedback on missing elements in an application, allowing developers to address these issues. Applications are generally not passed to a reviewer until the FDA considers them complete, ensuring efficient review processes.
VERBATIM QUESTION: For applications deemed incomplete, is there a standard approach to working with the FDA to address missing elements?
VERBATIM ANSWER: And then they give that over to the assigned contact and that contact can provide that feedback to the developer. That is okay your application, you know, looks complete and we're in a holding pattern right now. And if you notified then you have confirmation of notification from us. That will happen. That doesn't have to wait on a reviewer. But also that contact can say, "Oh we took a look at it. We don't necessarily have many concerns at the moment but we noticed that you have these missing elements so that you can work on those." And those can be provided because we actually probably in most cases won't hand that application over to a reviewer until we think that the application is complete so the reviewer's making the most efficient use of their time and as rapidly as possible reaching authorization decisions for the items that are on their plate and they're not holding in holding patterns with a number of different developers.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Incomplete application procedures, FDA feedback process, Reviewer prioritization
REVIEW FLAG: False

QA Block 12-11
CLARIFIED QUESTION: Does the FDA perform any prioritization review on applications before they are fully complete, and if so, how does this impact the workflow?
CLARIFIED ANSWER: The FDA performs an initial review to determine if an application falls into a higher priority category or contains potential risks to public health, which can affect prioritization. Applications are not handed over for full review until complete to maximize efficiency.
VERBATIM QUESTION: Does the FDA perform any prioritization review on applications before they are fully complete, and if so, how does this impact the workflow?
VERBATIM ANSWER: Well there is no limit. And what we do when we receive applications is, we have our expert review staff take a quick look at it and they do a couple of really key things when they take a good look at it. First of all does it fall into one of FDA Webinar these higher priority buckets that requires or would benefit, public health would really benefit from an authorization coming sooner than later? And then second are there any issues that we see? And that is, are there any performance characteristics, issues that would suggest there would be any sort of risk to public health? If there is that does get put into a higher priority bucket so that we can reach out to the developer and likely ask for some more information about what's going on. And, you know, and deal appropriately with the response that we get. And we have denied a number of assays that have fallen into that category already. And we maintain some of that list on our Web site. So the other thing they - we want them to do is note if there's any missing pieces to the application. And then they give that over to the assigned contact and that contact can provide that feedback to the developer. That is okay your application, you know, looks complete and we're in a holding pattern right now. And if you notified then you have confirmation of notification from us. That will happen. That doesn't have to wait on a reviewer. But also that contact can say, "Oh we took a look at it. We don't necessarily have many concerns at the moment but we noticed that you have these missing elements so that you can work on those." And those can be provided because we actually probably in most cases won't hand that application over to a reviewer until we think that the application is complete so the reviewer's making the most efficient use of their time and as rapidly as possible reaching authorization decisions for the items that are on their plate and they're not holding in holding patterns with a number of different developers. So hopefully that's helpful and answers your question.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA application prioritization, Application workflow, Initial completeness review
REVIEW FLAG: False

QA Block 12-12
CLARIFIED QUESTION: What actions should test developers take to ensure their EUA submission aligns with the honor system for test validation?
CLARIFIED ANSWER: Under the honor system, test developers must notify the FDA of test validation before submission and submit their EUA within a certain timeframe. The FDA conducts a quick review to address priorities, missing elements, or public health concerns.
VERBATIM QUESTION: What actions should test developers take to ensure their EUA submission aligns with the honor system for test validation?
VERBATIM ANSWER: Well if we see any elements that are missing as called out in the guidance as far as what's allowed via an allowed notification option, we would work with you on that to make sure that those things are - have been validated for example. So if there's clearly something missing like, you know, there's no - but again the notification process can happen before the submission right. So we're - this is the honor system that you notify us that you've validated your test and then you have a certain period of time to submit the EUA. Once we get it then we will do a quick review to make sure what prioritization that gets and if there are any missing elements and if there is, you know, any concerns, public health concerns okay?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission process, Honor system for validation
REVIEW FLAG: False

### removed qa blocks
QA Block 1-3
CLARIFIED QUESTION: Can healthcare providers order tests for screening purposes even if they are not labeled as such?
CLARIFIED ANSWER: Healthcare providers may order tests for screening even if they are not labeled as such. Considerations include test performance, turnaround time, and the broader testing program.
VERBATIM QUESTION: Can healthcare providers order tests for screening purposes even if they are not labeled as such?
VERBATIM ANSWER: We indicated in our FAQ that healthcare providers may order tests that are not specifically labeled for screening. They may order such tests for screening even if they're not labeled that way. And we include in our FAQ some considerations for healthcare providers including considering the performance of the tests that they're ordering considering the turnaround time and considering different testing approaches depending on the performance of the tests and the overall testing program that they're incorporating a test into.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Screening tests, Healthcare providers, Test labeling
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Does the FDA require any specific process to verify that instructions and components for the SalivaDirect test are followed correctly?
CLARIFIED ANSWER: FDA requires labs to follow authorized instructions provided by Yale and ensure they acquire all necessary components to perform the SalivaDirect test as authorized, but labs do not need their own EUA.
VERBATIM QUESTION: Does the FDA require any specific process to verify that instructions and components for the SalivaDirect test are followed correctly?
VERBATIM ANSWER: A laboratory that has provided the authorized instructions for use by Yale and is designated as an authorized lab under the EUA by Yale does not need to get their own EUA. This is sort of, you know, similar to a distributed test kit accept that the components that are specified in the authorized instructions for use are generally all commercially available. So they're sort of required but not provided components of the authorized test. So Yale would provide the authorized instruction for use and the laboratory would acquire all of those components and perform the test as authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SalivaDirect test, FDA authorization process, Laboratory instructions
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: Would submitting a semi-quantitative assay first expedite the EUA process compared to starting with a fully quantitative assay?
CLARIFIED ANSWER: Submitting a semi-quantitative assay first could expedite EUA authorization since quantitative assays require more validation. FDA recommends discussing this through a pre-EUA exchange.
VERBATIM QUESTION: Would submitting a semi-quantitative assay first expedite the EUA process compared to starting with a fully quantitative assay?
VERBATIM ANSWER: I think, you know, having a conversation, you know, through a pre-EUA exchange with our reviewers would be good in this space. It, you know, there is going to be more validation for - required for quant assay. And so if you want to, you know, sort of have an EUA authorization as quick as possible doing the semi quant first and following-up with the full quant may make a good strategy for you. But we're open to either.
SPEAKER QUESTION: Jess Terivery
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA strategy, semi-quantitative assays, quantitative assays
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Do schools need a CLIA certificate of waiver if a school nurse performs COVID-19 testing?
CLARIFIED ANSWER: Schools need a CLIA certificate of waiver if a school nurse is performing COVID-19 testing. However, if testing is done by individuals or parents without staff assistance, it falls under the non-laboratory use template.
VERBATIM QUESTION: Do schools need a CLIA certificate of waiver if a school nurse performs COVID-19 testing?
VERBATIM ANSWER: If it is, you know, in a school we do have, you know, we have had discussions with the CLIA program at CMS and they do provide CLIA certificates of waiver to schools. They have programs in place to do that, you know, on a broad, you know school district level for example. And if it is a situation where, you know, as you suggested perhaps the school nurse is providing the test and performing the test, that is a situation where CMS would expect the school to have a certificate of waiver to provide that testing. But if it is a situation where the individual or perhaps or their parent or guardian is performing the testing without the assistance of a personnel from the facility that would be - that would fall under the new non-laboratory use template.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA certificate for schools, School nurse testing, Non-laboratory COVID-19 testing
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: Does FDA expect an EUA submission for laboratories using the CDC assay?
CLARIFIED ANSWER: The FDA expects laboratories using the CDC assay to submit an EUA request for their test. Labs can reference the CDC EUA to avoid repeating validation already conducted by CDC.
VERBATIM QUESTION: Does FDA expect an EUA submission for laboratories using the CDC assay?
VERBATIM ANSWER: Yes, we would want you to come in with an EUA request for your test. But you could in your EUA request reference the CDC EUA so you would not have to repeat the validation that they have in their EUA. We could leverage that.
SPEAKER QUESTION: BJ Tatel
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission for CDC assay, Laboratory validation requirements
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: Does the notification process for a test carry the same weight as announcing an EUA authorized test?
CLARIFIED ANSWER: The FDA states that point-of-care tests requiring EUA authorization are prioritized, as they cannot launch without it. Tests eligible for the notification process carry less priority compared to those requiring EUA for specific settings.
VERBATIM QUESTION: Does the notification process for a test carry the same weight as announcing an EUA authorized test?
VERBATIM ANSWER: So, you know, anything that's the point of care if it's truly going to be used at point of care does require an EUA authorization to deem it as CLIA waived or non-lab or home collection situations. So those all require EUAs and so they aren't allowed to launch for those indications until they have that EUA authorization. So those are the ones in greatest need to be able to offer that test in the US. So those and those do get a higher priority because of that requirement. So if all the point of care test information is in the application for the reviewer to review then they would receive - that would receive a higher priority in our review process because they can't notify and launch point of care.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, Test prioritization, Point-of-care tests
REVIEW FLAG: False

QA Block 10-9
CLARIFIED QUESTION: Under what conditions is EUA submission required for tests that involve home collection of saliva samples?
CLARIFIED ANSWER: EUA submission is required for home collection or non-lab, non-health care setting collections. For collections in healthcare facilities under observation, submission is not required.
VERBATIM QUESTION: Under what conditions is EUA submission required for tests that involve home collection of saliva samples?
VERBATIM ANSWER: It's only if you're going to go into the home collection type situation that - and other non-lab non-health care setting collection where EUAs is required for that particular purpose. But if it's going to be collected in a healthcare facility under an observation you know, then you don't need to submit. The lab that's doing that doesn't need to submit that data to the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, Home collection, Saliva sample validation
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 06:44:56 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 12
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What changes were made in the recent FAQ updates regarding screening and asymptomatic testing?
QI 1-2: What are the validation expectations for tests intended for screening asymptomatic individuals?
QI 1-3: Can healthcare providers order tests for screening purposes even if they are not labeled as such?
QI 1-4: What considerations should healthcare providers evaluate when ordering tests not labeled for screening purposes?
QI 1-5: How does the FDA categorize self-tests as 'non-lab' or 'at-home' tests?
QI 1-6: What are the specific CLIA requirements for non-lab or self-testing scenarios discussed by the FDA?
QI 1-7: What is the role of facility personnel in settings like schools or sporting events for self-testing?
QI 1-8: What templates are available for developing non-laboratory diagnostic tests?
QI 1-9: Under what conditions can laboratories other than Yale perform the SalivaDirect test under its EUA?
QI 1-10: What components and procedures must laboratories follow to perform the SalivaDirect test as authorized?
QI 1-11: What distinguishes rapid turnaround point-of-care diagnostic tests from other tests in terms of authorization priorities?
QI 1-12: What characteristics make a test suitable for detecting individuals with high viral loads during the acute symptomatic phase?
QI 1-13: Are there specific FDA recommendations for expanding the development of diagnostic tests for point-of-care use?

#### Section 2 of 12
##### Explicit Questions Extraction
QE 2-1: Do labs that contact Yale and get approval to run the SalivaDirect test need to submit validation data to the FDA, or can they start running the test without it?
QE 2-2: What is the third authorized antigen test listed on the FDA website, and is it already posted?

##### Implicit Questions Extraction
QI 2-1: What requirements or conditions must a laboratory meet to be designated as an authorized lab under the SalivaDirect EUA?
QI 2-2: Are the components specified in the SalivaDirect test's authorized instructions all commercially available, and is the lab responsible for acquiring them?
QI 2-3: Does the FDA require any specific process to verify that instructions and components for the SalivaDirect test are followed correctly?

#### Section 3 of 12
##### Explicit Questions Extraction
QE 3-1: What is the FDA's perspective on semi-quantitative tests versus fully quantitative tests?
QE 3-2: Would it be simpler to submit a semi-quantitative test first and then follow up with a fully quantitative test, or would both require the same rigor in the EUA application process?

##### Implicit Questions Extraction
QI 3-1: What is the FDA's perspective on the use of calibration ranges versus standard curves in COVID-19 diagnostic tests?
QI 3-2: Does the FDA have specific guidance on the clinical applications of semi-quantitative and fully quantitative serology assays?
QI 3-3: How can developers use pre-EUA exchanges to clarify validation requirements for different types of assays?
QI 3-4: What additional validation is required for a fully quantitative assay compared to a semi-quantitative assay?
QI 3-5: Would submitting a semi-quantitative assay first expedite the EUA process compared to starting with a fully quantitative assay?

#### Section 4 of 12
##### Explicit Questions Extraction
QE 4-1: Should we submit EUA requests for non-facility use tests using the regular molecular diagnostic templates for manufacturers?
QE 4-2: Is the non-laboratory template suitable for tests performed outside home environments, such as schools or workplaces?
QE 4-3: Do schools need a CLIA certificate of waiver if a school nurse performs COVID-19 testing?
QE 4-4: Would schools need a non-laboratory template if students or their guardians perform the tests without assistance from personnel?
QE 4-5: Do pharmacies need a CLIA waiver certificate if their personnel assist in COVID-19 testing?
QE 4-6: If a pharmacy provides only self-tests that individuals perform themselves, is a CLIA certificate still required?
QE 4-7: Are developers required to submit two different templates (point of care and non-traditional use) based on the testing locations?
QE 4-8: Can portions of the point of care and non-laboratory templates be combined into one submission based on specific needs?

##### Implicit Questions Extraction
QI 4-1: What are the specific requirements for obtaining a CLIA certificate of waiver for non-traditional testing environments like workplaces or schools?
QI 4-2: Can a self-administered test authorized under the non-lab template also be used in CLIA-waived environments by healthcare providers without separate authorization?
QI 4-3: What additional safety considerations does the FDA evaluate for tests intended for use on children by adults in non-laboratory settings?
QI 4-4: Are there any limitations on the types of populations (e.g., children) or settings (e.g., schools, workplaces) that can use tests authorized under the non-lab template?
QI 4-5: What criteria make a test eligible for authorization under the non-laboratory use template versus the point-of-care template?
QI 4-6: Can tests authorized for prescription use in non-laboratory settings also be made available over the counter without a separate EUA?

#### Section 5 of 12
##### Explicit Questions Extraction
QE 5-1: How is FDA helping CDC to launch multiplex combo flu and SARS CoV-2 assays to private labs?
QE 5-2: Will the launch process for multiplex combo flu and SARS CoV-2 assays differ from the FDA webinar's previous version?
QE 5-3: What further recommendations do you have for laboratories using CDC's assay data for validation?
QE 5-4: Does FDA expect an EUA submission for laboratories using the CDC assay?

##### Implicit Questions Extraction
QI 5-1: What steps can laboratories take to develop new tests based on the CDC's multi-analyte assay?
QI 5-2: What type of information is the CDC providing to laboratories to encourage test development?
QI 5-3: What does 'right of reference' mean in the context of using CDC EUA information for test development?
QI 5-4: Is it mandatory for developers to conduct their own validation if using CDC's EUA as a reference?
QI 5-5: Will the FDA accept an EUA submission that leverages validation data from the CDC's EUA?
QI 5-6: What components (e.g., primers, probes, reagents) are required to independently validate a test based on the CDC template?
QI 5-7: Are there specific guidelines for ordering materials like primers and probes for validation?

#### Section 6 of 12
##### Explicit Questions Extraction
QE 6-1: Can the population be enriched to include those who test positive in either the non-laboratory or a healthcare setting?
QE 6-2: Are there limitations to the assays that can be used to confirm a positive case when enriching the population?

##### Implicit Questions Extraction
QI 6-1: Will the FDA antigen template be updated to clarify enrichment processes for healthcare settings?
QI 6-2: Does the FDA require developers to address potential bias for visually read antigen tests as part of the study design?
QI 6-3: Is it necessary to consult the antigen team before implementing enrichment methods in a study?

#### Section 7 of 12
##### Explicit Questions Extraction
QE 7-1: What is the process for assigning a test submission into the triage program and how does a test submission get out of it?
QE 7-2: Does the notification process for a test carry the same weight as announcing an EUA authorized test?
QE 7-3: Is the prioritization based on CDC categorization of how a test will be used or by some other method?
QE 7-4: Does a point of care test, especially a rapid test, receive higher priority than a test that can be launched in a high complexity lab?

##### Implicit Questions Extraction
QI 7-1: What constitutes a high-priority category for COVID-19 diagnostic test submissions?
QI 7-2: How does the notification pathway differ from the EUA authorization process in terms of eligibility to launch a test?
QI 7-3: What kind of status updates should a developer expect when their application is placed into the secondary program (triage program replacement)?
QI 7-4: What specific information is required for a point-of-care test application to ensure prioritization under the review process?

#### Section 8 of 12
##### Explicit Questions Extraction
QE 8-1: Does a serology test using blood as a sample require the person taking the sample to be a lab employee, or can it be a phlebotomist or clinician?
QE 8-2: What are the requirements if a serology test uses whole blood from a blood draw?
QE 8-3: What are the requirements if a serology test uses a finger-stick sample?

##### Implicit Questions Extraction
QI 8-1: Is a finger-stick method authorized under an EUA for transporting the sample with a device?
QI 8-2: Can whole blood, serum, or plasma samples collected off-site be tested in a high-complexity lab if the test is authorized for those sample types?
QI 8-3: Does the notification process allow for transporting collected blood samples to high-complexity labs for testing?

#### Section 9 of 12
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 9-1: What are the state-specific regulations regarding specimen collection for COVID-19 testing compared to federal CLIA requirements?
QI 9-2: Does a specimen collection-only site need to be staffed by personnel with laboratory-specific training?
QI 9-3: What level of training or licensure is required for individuals performing healthcare provider-observed specimen collection?
QI 9-4: Is specimen collection for COVID-19 diagnostics under the FDA's regulatory purview?
QI 9-5: Should developers consult CMS or CLIA about requirements for specimen collection at non-laboratory sites?

#### Section 10 of 12
##### Explicit Questions Extraction
QE 10-1: How did the Yale team and others address the issue of inconsistencies with saliva in direct antigen tests?
QE 10-2: Where can I find the EUA-accepted tests on the FDA website?

##### Implicit Questions Extraction
QI 10-1: What is the FDA's recommended comparator sample type for validating saliva as a respiratory sample in COVID-19 tests?
QI 10-2: Why does the FDA have ongoing concerns about saliva as a sample type for COVID-19 testing?
QI 10-3: What are the specific circumstances under which a lab does not need to submit EUA data for validation of saliva use?
QI 10-4: What are the FDA recommendations on the distribution of viral load ranges needed for saliva test validation?
QI 10-5: How could overloading viral load samples at either extreme of the spectrum affect saliva test validation performance?
QI 10-6: Is it necessary to submit validation data for saliva if samples are collected in a healthcare facility under supervision?
QI 10-7: Under what conditions is EUA submission required for tests that involve home collection of saliva samples?

#### Section 11 of 12
##### Explicit Questions Extraction
QE 11-1: How does the FDA determine complexity for a point of care test to deem it sufficient for point of care designation?
QE 11-2: Are certain assay types more difficult to make a point of care case for than others?
QE 11-3: Would the FDA consider a 96 well plate-based assay for point of care testing if it met the criteria?
QE 11-4: Is the bar higher in terms of validation for a test to qualify as point of care compared to a lab-based assay or is it comparable or lower?

##### Implicit Questions Extraction
QI 11-1: What are the specific requirements for performing guard band or flex studies for point of care tests?
QI 11-2: Can devices that were previously CLIA-waived skip additional point of care studies if their workflows remain unchanged?
QI 11-3: What are the FDA's requirements for devices seeking point of care authorization to demonstrate they are easy to perform by non-laboratorians?
QI 11-4: How does the FDA evaluate instruments that have not been waived prior to the pandemic for point of care testing?
QI 11-5: What criteria does the FDA use during the EUA review process to determine if a device qualifies for point of care testing?
QI 11-6: Under what conditions could devices that usually require laboratory settings, such as those utilizing 96-well plates, be considered for point of care authorization?
QI 11-7: Does the FDA prefer self-contained point of care assays to prevent contamination?

#### Section 12 of 12
##### Explicit Questions Extraction
QE 12-1: Is there a limit to how long a test can be on the notification pathway without substantive review or authorization by the FDA?
QE 12-2: After submitting a test for notification, will we receive confirmation of notification if missing elements are identified by the triage reviewer, or only after the application is administratively complete?

##### Implicit Questions Extraction
QI 12-1: What criteria does the FDA use to identify high-priority applications for review?
QI 12-2: What are the key performance characteristics that might lead to an application being considered a public health risk?
QI 12-3: What happens if an application submitted for notification is incomplete?
QI 12-4: Is a list of denied assays made publicly available, and how can developers find this information?
QI 12-5: Can the FDA provide feedback on missing elements before an in-depth review is initiated?
QI 12-6: Do test developers need to explicitly specify notification in their EUA submission email to be listed as a notified test?
QI 12-7: What happens after notifying the FDA about a validated test prior to EUA submission?
QI 12-8: For applications deemed incomplete, is there a standard approach to working with the FDA to address missing elements?
QI 12-9: Does the FDA perform any prioritization review on applications before they are fully complete, and if so, how does this impact the workflow?
QI 12-10: What actions should test developers take to ensure their EUA submission aligns with the honor system for test validation?
